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1 INTRODUCTION
1.1 CARDIOVASCULAR DISEASE
Cardiovascular diseases comprise especially the major disorders of the heart and the
arterial circulation supplying the heart, brain and peripheral tissues. Cardiovascular
disease is a term and includes following diseases (public health agency of Canada,
phac):
• ischemic heart disease, describes defects in the transport of blood to the heart,
• cerebrovascular disease, describes the malfunction of blood vessels to transport
sufficient blood to the brain and can lead to thrombosis or even stroke,
• peripheral vascular diseases, refers to an impairment of the blood supply to the
extremities,
• heart failure, describes an insufficient blood supply to the body and is often a
result of a myocardial infarct or a cardiomyopathy (heart muscle disease),
• rheumatic heart disease, starts with a bacterial infection in children and leads
to inflammation. This further can results in dysfunctions of the heart in adults,
• congenital heart disease, is an anatomic structural defect of the heart and can
vary in complexity.
Cardiovascular diseases have a common occurrence in most populations and a great
attendant mortality. Such diseases go along with loss of independence and impaired
quality of life as well as social and economic costs. Cardiovascular diseases are the
main cause of death in Austria (Statistik Austria, 2010). In 2009 43% of all deaths
were results of cardiovascular problems. This reflects a number of four out of ten
deaths caused mainly by heart attacks or strokes. But cardiovascular diseases are
not only a problem in Austria. They have become the predominant cause of death in
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many countries and in the whole world claiming 17.1 million lives a year (WHO, 2010).
Cardiovascular diseases occur equally in men and women. Known risk factors are
tobacco use, unhealthy diet and physical inactivity. These diseases can be prevented
by minimizing the known risk factors. Today we can see a decrease of 1.2% over
the last ten years, or even of 16% by considering the increase of elder people. Also
a reduction of 33% in the death rate of cardiovascular diseases due to improved
therapeutic applications and basic research were observed (Statistik Austria, 2009).
1.2 MYOCARDIAL REGENERATION
Heart failure is a result of myocyte hypertrophy and dysfunction as well as the
progressive loss of cardiomyocytes. Apoptosis, the programmed cell death plays a
critical role in this loss of cardiomyocytes and can rapidly lead to organ destruction
(Narula et al., 1996).
Today, the only available therapies to treat a heart failure are cardiac transplantation,
remodeling operations and pacing. Cardiac transplantations are the most radical,
because the disrupted heart gets replaced by a new functional donor heart. Another
possibility is partial transplantation by implanting left ventricular assist devices
permanently. Severe heart failures can be surgically treated by remodeling of the
left ventricle or by implanting a pacemaker that resynchronizes the heart. All these
therapies have their pros and cons so that the research in developing more effective
and improved therapies is of great interest. Great hope lies in a recently discovered
technique, myocardial regeneration, which allows the repopulation of injured tissues
with cells that are able to improve and enhance heart function. The research focuses
on finding such cells that represent an adequate source for regeneration of the injured
myocardium.
An old dogma, which could be disproved by Kajstura and colleagues (1998), says
that cardiac myocytes are not able to divide because of the fact that they are already
terminally differentiated. According to this old notion the injured heart is not able
to overcome the progressive loss of cardiomyocytes with new self-cardiomyocytes
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and consequently the heart do not feature some kind of self-repair mechanisms. But
Kajstura and colleagues could disprove the notion of the human heart to be a post-
mitotic organ. Indeed, they could show that in normal, healthy myocardium mitosis
was extremely infrequent, but in injured myocardium they could see a reenter of
cardiomyocytes into mitosis. Unfortunately, this self-repair mechanism of the injured
heart is not able to cover up the large deficit of cardiomyocytes. This limitation
makes an exogenous supply of cells necessary. An example of such exogenous source
of cells represents fetal cardiomyocytes. Fetal cardiomyocytes were used for cell
transplantation after a myocardial infarct (Leor et al., 1996). This group could show
that this transplanted cardiomyocytes were able to successfully engraft into infracted
myocardium thereby expressing gap junction. The transplanted cells were able to
survive in the disrupted area and lead to improved cardiac function.
Regardless of the breakthrough with fetal cardiomyocytes, research turned to usage of
skeletal myoblasts for cell therapy. With skeletal myoblasts they could overcome the
controversial problematic of ethic. Anyway, cells are more available, are more suited
for in vitro cultivation and are committed to the cardiac lineage which reduces the
prevalence of tumor development. Murry and colleagues (2008) could demonstrate
that skeletal myoblasts grafted into injured rat hearts had the potential to develop
into muscle tissue. Another study where skeletal myoblasts were engrafted into the
infarcted myocardium showed that systolic function and contractility was improved
(Taylor et al., 1998). At first glance these cells seem to be perfectly made for cell
therapy, but by closer attention these cells exhibit some limitations. One limitation
addresses the fact that fetal cardiomyocytes are able to express gap junctions and
thereby can interact with neighboring cells, while skeletal myoblasts lack this feature.
A more realistic source of cells for myocardial grafting turned out to be stem cells.
Stem cells are known to feature unique characteristics like plasticity which make
organs that harbor stem cells possible to get to a certain extent regenerated after
injury. Stem cells are able to regenerate tissues like skin, intestinal and pulmonary
mucosal and connective tissues. As already mentioned, the heart is considered as a
postmitotic organ, but again this notion could be disproved by the behavior of bone
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marrow stem cells. Bone marrow stem cells have the capacity to infiltrate into normal
and infarcted myocardium. This homing of stem cells is thought to be driven by
environmental factors in the injured tissue. Just arrived the infarcted myocardium,
bone marrow stem cells gave rise to new myocytes, endothelial cells and smooth
muscle cells thereby regenerating the infarcted myocardium (Orlic et al., 2002). Here
again, it was shown that the heart feature self-repair mechanisms after injury. Orlic
and colleagues were also able to demonstrate a decrease in infarcted area when
bone marrow cells were directly transplanted into infarcted myocardium. Autopsies
of female hearts who had received sex-mismatched bone marrow transplantation
revealed the presence of Y-chromosome-positive cardiomyocytes (Deb et al., 2003).
This result indicates that the cardiomyocytes originated from the transplanted bone
marrow and thus proved the remarkably potential of bone marrow stem cells to
infiltrate infarcted myocardium as Orlic and colleagues already demonstrated. These
new comforts revealed the potential of stem cells and consequently raised the interest
of further investigations in this area.
1.3 STEM CELLS
Stem cells have two major properties which make them very attractive in clinical
research. Firstly, they are provided with an unlimited self-renewing potential and
can be kept in an undifferentiated state. Secondly, their plasticity enables them to
differentiate into various cell types. These characteristic features make stem cells a
unique cell line.
Self-renewal is important to maintain the stem cell pool during injury and throughout
life. The process of self-renewal is not an easy one. Complex networks are necessary
to balance proto-oncogenes and tumor suppressors (He et al., 2009). Such genes are
involved in promoting or limiting self-renewal and are regulated by signals from the
stem cell niche. Without signals from the niche stem cells reside in a state of rest
with less division potential (Cheshier et al., 1998). But during tissue injury stem cells
get activated and enable tissue repair by enhanced self-renewal (Wilson et al., 2008).
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So self-renewal is dependent on signals from the niche. Such microenvironments in
which stem cells reside are important to balance stem cell activity and without their
niche stem cells lose their self-renewal capacity and start to differentiate. Therefore,
these niches are not only necessary for tissue repair, they are also important to
maintain stem cell identity. The discovery of the importance of such niches emerged
firstly by the removal of stem cells from their environment. Without the extrinsic
signals provided from the niche, stem cells lost their proliferative potential. Since
then, stem cells are thought to need distinct environments where they are associated
with tissue-cells and signals emerging from the microenvironment (Schofield, 1978).
The term "niche" was created. Today we know about the existence of stem cell niches
in the intestinal, neural, epidermal and hematopoietic system (Figure 1.1).
Figure 1.1: Stem cell niches balance stem cell activity. Niche cells interact indirectly
with stem cells and control their activity. These cells control the differentiation and
division of stem cells.Distinct stimuli activate stem cell division. Thereby one daughter
cell remains attached to the niche while the other start the differentiation program
(Spadling et al., 2001).
Another special feature of stem cells is pluripotency. So far, three transcriptional
factors are known to control stem cell genes involved in maintaining pluripotency or
activate genes responsible for repressing differentiation. One of the critical factors is
the transcription factor Oct3/4. Oct3/4 controls the fate of embryonic stem cells not
simply by an on-off control system, but by the level of Oct3/4 itself. Niwa and col-
leagues showed that an up- or downregulation of Oct3/4 expression results in diverse
differentiation programs, while a critical amount is necessary to maintain pluripo-
tency. Further studies on this issue revealed other factors necessary in maintaining
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pluripotency. Nanog is expressed in undifferentiated murine embryonic stem cells, but
absent in differentiated cells (Mitsui et al., 2003). Nanog is like Oct3/4 important for
the maintenance of pluripotency and interplays with Oct3/4 (Chambers et al., 2003).
Another today known key factor is Sox2 which acts on Nanog, Oct3/4 and Sox2 itself.
Sox2 is maybe not as essential as Oct3/4 in maintaining embryonic stem cells, but
Sox2 has its critical role in stabilizing cells in the pluripotent state (Masui et al., 2007).
Murine embryonic stem cells have the attractive characteristic to differentiate to
every type of cell in vivo promising great hope in cell-based therapies (Murry and
Keller, 2008). They can be isolated from the inner cell mass of the blastocyst and
can be kept as in vitro cultures (Martin, 1981). In vitro, the cells maintain their
differentiation potential and provided with appropriate stimuli they can be induced to
differentiate into diverse cell types. Collectively, embryonic stem cell differentiation
can be directed into the ectodermal, mesodermal and endodermal lineage (Desbaillets
et al., 2000). LIF/STAT3 -dependent signaling plays a critical role in maintaining
pluripotency and self-renewal of in vitro cultivation (Cartwright et al., 2005). To
keep embryonic stem cells in an undifferentiated state the presence of LIF or feeder
layers is indispensable. Differentiation of stem cells into somatic cell types occurs
via precursor cells (also often called somatic stem cells). While embryonic stem cells
are pluripotent, tissue-specific stem cells are restricted to their lineage. As the term
’tissue-specific’ reveals this type of stem cells can only generate cell types of the tissue
they reside in.
Today three methods are used to promote differentiation of embryonic stem cells: the
culture of ESCs directly on supportive stromal layers, the culture as monolayers and
the generation of embryoid bodies. It is debatable which of these methods is classified
as the best, but all proved the potential of embryonic stem cells to differentiate in
vitro to a wide spectrum of cell types.
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1.3.1 Embryoid Bodies
A promising approach in determining appropriate conditions for differentiation of
embryonic stem cells was made by the creation of embryoid bodies. Embryoid bodies
are 3D spherical structures of cell aggregates hold in suspension, on methylcellulose
or as hanging drops. Dependent on the aggregate procedure differentiation reveals
distinct cell types (Figure 1.2).
Embryoid bodies mimic early embryonic developmental stages until gastrulation and
give rise to most if not all somatic cells of all three germ layers (Desbaillets et al.,
2000). Embryoid bodies made it easy to investigate developmental issues and reduced
the need of peri-implanted embryos. Further they are suited for the characterization
of the function of precursor cells or of given null mutants. But we should be aware
that embryoid bodies are restricted in their developmental potential. They possess no
polarity or body plan and so no viable embryo can be created what is an important
fact in ethical issues.
With the method of hanging drops we are able to create embryoid bodies with defined
cell number and shape. This procedure is probably the easiest to control.
Figure 1.2: Three methods for embryoid body formation. These methods differ in
their culture conditions and the following differentiation into distinct cell types. First
procedure describes the possibility of aggregates to attach at a methylcellulose layer.
Second opportunity is to let aggregates hang from the lid, which separate the aggregates
from each other. Last method explains the cultivation in suspension where aggregates
can float (Desbaillets et al., 2000).
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1.3.2 Differentiation Potential
Developmental biology deals with the formation of organisms and with its associated
cellular processes. Gastrulation is an important stage during embryogenesis where in-
tense cell migration proceeds to generate the three germ layers: mesoderm, ectoderm,
endoderm. Studies revealed that early lineage commitment occurs not by chance
rather by spartial and temporally specification of cell populations (Kinder et al.,
1999). During gastrulation the primitive streak is formed transiently at the posterior
end of the embryo. This includes also the movement of cells over the primitive streak
which in turn gives rise to the mesoderm and the definitive endoderm. The ectoderm
does not as mesoderm and definitive endoderm derive through migration of cells
through the primitive streak. It derives from the anterior region of the epiblast
(Figure 1.3). The primitive streak is distinguished by different expression profiles
along its axis (Kinder et al., 2001), whereas some genes like Brachyury are expressed
over the hole primitive streak (Kispert and Hermann, 1994). Beside the diverse
expression profiles, cells of the primitive streak showed also varied differentiation
potentials what concludes the presence of a prospective fate map (Smith et al., 1994).
Figure 1.3: Formation of the three germ layers during gastrolation. A: The process of
gastrulation leads to the formation of ectoderm, endoderm and mesoderm. Each layer is
fated to generate distinct types of cells in further developmental stages. B: Movement of
cells located at distinct positions at the primitive streak explains the formation of the
three germ layers (Murry and Keller, 2008).
These findings suggested that the regions of the primitive streak differ in their sig-
naling environments, which further concluded the induction of diverse lineages. In
vitro studies revealed an insight into the regulatory mechanisms underlying germ
layer formation. Different culture conditions mimicking probably distinct signaling
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environments lead to the formation of cell types typical for each germ layer.
Embryoid bodies cultured in the presence of activin A or exposed to reduced serum
revealed induction of endoderm formation. A population of cells expressing Brachyury
showed differentiation to endoderm and revealed also a potential for mesoderm for-
mation (Kubo et al., 2003). While Brachyury+ cells adopt a line between endoderm
and mesoderm, Foxa2+ cells seemed to be more restricted in their differentiation fate
(Figure 1.3,B). Foxa2 promotes an endodermal fate (Burtscher and Lickert, 2009).
Endodermal cells emerge to cells comprising the embryonic gut and in following
developmental processes form the gastrointestinal tract, liver and pancreas.
The ectodermal layer emerges to the neural lineages and skin. The ectodermal
induction proceeds without presence of serum or other primitive streak inducers and
is therefore often said as default pathway. Ying et al. demonstrated that neural fate
is decided by simple elimination of inductive signals for alternative fates, but requires
autocrine fibroblast growth factor (Ying et al., 2003). In vivo, retinoic acid has great
influence during developmental decisions affecting mesodermal or ectodermal cell
differentiation. It controls the fate of cells to become either cardiac cells or neurons
by inducing neuronal differentiation and thereby inhibiting cardiomyogenesis at the
same time. While high concentrations of retinoic acid resulted in the development of
neurons, low concentrations led to differentiation of cardiomyocytes (Aouadi et al.,
2006).
Mice lacking nodal died between E8.5 and E9.5 due to the failure to form mesoderm
(Pfendler et al., 2000). Similar results were seen by deletion of Bmp-5 gene. Because
of the observed defects it can be assumed that these two genes are among others
important in mesoderm formation. Also an important gene involved in mesoderm
formation is Brachyury T. Without Brachyury not enough mesoderm is produced
(Wilkinson et al., 1990). Therefore, an interplay of distinct markers specify the
formation of the mesoderm. The formation of beating cardiomyocytes from mouse
mesoderm seemed to be directed and enhanced by the cardiac transcription factors,
Gata4 and Tbx5 which was proved by alpha-tropomyosin and cardiac troponin T
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expression (Takeuchi and Bruneau, 2009). Expression of cardiac marker cTnT is
restricted to the mesodermal lineage.
1.4 HEART DEVELOPMENT IN THE MOUSE
One topic of developmental biology deals with heart formation and the origin and
role of heart-forming cells. The heart field is explained as the mesodermal area
containing the cardiac progenitor cells that are finally destined to form the heart.
Such precardiac cells start to migrate from the epiblast through the primitive streak
and assemble the myocardial plate (Fishman and Chien, 1997). This is followed by the
generation of the heart tube. Chamber formation is driven by looping morphogenesis
separating the heart in four different chambers (Christoffels et al., 2000).
The heart is the first functional organ developed during embryonic development
and consists of three layers: endocardium, myocardium and epicardium (Manasek,
1969). During gastrulation three germ layers, ectoderm, mesoderm and endoderm are
generated that serve as a blueprint for organogenesis. Cells underlie a fate map and
are therefore destined to build up distinct organs. One of the germ layers, the meso-
derm is known to drive cardiomyogenesis leading to the formation of hematopoietic,
vascular, cardiac and skeletal muscle lineages (Brand, 2003). Heart development is a
strictly regulated process. Starting with the early mesoderm the cardiac development
reaches its final by the formation of the four-chambered organ by continuous remod-
eling processes that are temporally and spatially controlled (Christoffels et al., 2000).
Heart formation is driven by the differentiation of embryonic stem cells to an inter-
mediate stage to the so called precursor cells. The following stepwise commitment of
cardiac precursor cells lead to terminally differentiated cells making up the adult heart.
In early stages of embryonic development we can find precursor cells residing in the
mesoderm expressing Brachyury T. Brachyury T is a marker for the onset of meso-
derm induction. During first steps in cardiomyogenic development these cells change
their expression profile to Mesp1 expression. Mesp1 -null mice featured malformations
of the heart indicating that Mesp1 plays a critical role in early cardiomyogenesis.
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Mesp1 -expressing cells generate the cardiovascular system, myocardium and endo-
cardium what was revealed by lineage studies (Saga et al., 2000). Mesodermal cells
start to migrate and to expand forming the cardiac crescent. Mesp1+ cells are fated
to be precursors of cardiac progenitor cells that turn to express Nkx2.5 and Isl-1. By
this, precursor cells got committed to the cardiac lineage irreversibly. Isl-1 -expressing
cells migrate into the heart and lose most of the expression potential upon differ-
entiation. Sun et al. demonstrated in lineage studies that Isl-1+ cells encompass
endothelial and smooth muscle cells in the adult heart. This in turn, made Isl-1 an
adequate marker for cardiac cells in the heart. Mutant Nkx2.5 -/- embryos showed
abnormal heart development. In conclusion it seemed that Nkx2.5 is essential for
survival and proliferation of precursor cells (Lyons et al., 1995).
Diverse genes have an important role during heart formation controlling thereby
genetic pathways of embryogenesis. Disruptions in these genetic pathways can lead to
cardiac malformations in humans. Therefore it is not surprising that heart diseases are
associated with abnormal cardiac gene expression profiles. Important transcriptional
regulators are said to be the Nkx2.5 homeodomain protein, members of the MEF2
family and HLH myogenic proteins (Fishman and Chien, 1997).
Figure 1.4: Schematic draw of heart development and the role of putative progenitor
cells. Mesodermal cells expressing Brachyury T turn to express Flk-1 and Mesp1 which
results in the induction of cardiac development. A final commitment is activated by
changing the expression profile to Nkx2.5 and Isl-1. Cells expressing these markers are
assumed to be progenitor cells that form during several differentiation processes the
adult heart (Wu et al., 2008).
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1.4.1 Nkx2.5 Homeodomain Protein
The Nkx2.5 gene is the vertebrate homolog of tinman and is a cardiac-specific
homeobox gene playing a critical role in heart development. As already mentioned
mesodermal cells turn to express Nkx2.5 during heart development, which indicates
the first commitment of cells to the cardiac lineage. Therefore Nkx2.5 can be de-
scribed as an early marker in cardiac development which is still expressed throughout
the developing heart and even in the adult heart. One important enhancer in the
activation of Nkx2.5 expression during heart development seemed to be GATA4 (Lien
et al., 1998).
Mutations in the human Nkx2.5 gene results in heart disease causing abnormalities
of the atrioventricular conduction system and the heart itself (Schott et al., 1998).
A study by McElhinney and colleagues showed that only a small percentage of
heart diseases originate from mutations in the coding region of the Nkx2.5 gene. In
many cases mutations were missense and observed outside the homeodomain indi-
cating the importance of this region in cardiac development. Tanaka and colleagues
demonstrated the effect of Nkx2.5 gene disruption in the adult heart by revealing its
influence on the late differentiation potential of cardiac myocytes.
In summary, Nkx2.5 plays a critical role in heart development and in cardiac genetic
pathways thereby influencing downstream cardiac genes (Lyons et al., 1995).Today
it is thought that Nkx2.5 is critical for cardiac cell fate determination, though it is
insufficient to do it all on its own.
A stable CVPC clone A5 cell line called A5-CSX was created by T. Gottschamel
(2010) carrying an EGFP reporter gene and a puromycin resistence cassette located
in the Nkx2.5 gene.
The A5-CSX cell line was produced by homologue recombination with the pCsx-
EGFP-PP-DT vector, which contains homologue sequences to the murine Nkx2.5
gene which are interrupted by the selection marker puromycin and an EGFP reporter
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gene. The A5-CSX cell line carries an EGFP marker gene under the control of the
Nkx2.5 promoter. Because EGFP expression correlates with the Nkx2.5 expression
we are able to display differences in Nkx2.5 expression by detecting the EGFP signal
by diverse methods like western blotting, immunofluorescence mircroscopy and FACS
analysis. The differentiation as well as the self-renewing potential of A5-CSX cells
was not influenced by the knock in (Gottschamel, 2010). Therefore the A5-CSX
reporter cell line is an adequate tool for the investigation of factors influencing Nkx2.5
expression and so cardiomyogenesis.
1.5 CARDIAC PROGENITOR CELLS
The obsolete notion of the adult heart as being a postmitotic organ with the absence
of resident stem cell populations is today very well undermined by diverse studies. Re-
sults indicated the existence of stem cell-like populations in the fetal and adult heart
and abolished the old dogma of a missing self-renewal potential. This assumption is
strengthened by the successful isolation of cardiac stem cell-like populations from the
adult heart expressing defined markers. By now Sca-1 or c-Kit are common markers
for cardiac stem cells that hold good in the identification and isolation of these cells.
Cells expressing these markers promise a great regenerative potential of injured tissue.
The number of Sca-1 expressing cells was enhanced after myocardial infarction indi-
cating their potential in promoting heart tissue repair (Wang et al., 2006). Wang
and colleagues succeeded in the isolation of Sca-1+/ CD31 - cells from the heart
of mice. In vitro cultivation and differentiation studies revealed their potential to
differentiate to both endothelial and cardiomyocyte cells. Transplantation of these
cells into disrupted murine hearts revealed an improvement of heart function as well
as an enhancement of cardiomyocyte regeneration.
Transgenic mice featuring EGFP under the control of the c-kit locus showed a maxi-
mum of c-kit+ cells at postnatal day 2, whereas only very few cells were observed in
the adult heart. But disrupted adult hearts expressed c-kit positive cells in a higher
extent especially in and surrounding the infarct tissue. Isolation of c-kit+ cells and
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further in vitro investigations confirmed the idea of c-kit+ cells to be precursor cells,
because these cells differentiated into endothelial, cardiac and smooth muscle cells
during in vitro cultivation (Tallini et al., 2009).
1.6 ISOLATION OF PROGENITOR CELLS
Two different, but similar methods were used by our group to isolate somatic stem
cells. To ensure a successful isolation and cultivation of somatic stem cells they were
provided with conditions similar with that they are confronted in vivo. Thereby it was
attention made on the fact that stem cells need distinct culture conditions to maintain
their self-renewal and differentiation potential. Thus, an artificial niche was created to
mimic such conditions. This artificial niche consists of both LIF -producing fibroblasts
and embryonic stem cells. Investigations on the self-renewing potential of embryonic
stem cells showed already the importance of the LIF signaling pathway (Cartwright
et al., 2005). The same necessity of LIF was supposed on cardiac stem cells to
provide an artificial in vitro niche. Not only feeder cells, but also ESC contributed to
the artificial niche by providing distinct growth factors and to ensure physical contact.
For the isolation of cardiovascular progenitor cells (CVPCs) the hearts from new-
born 129v mice carrying a neomycin resistance cassette in one allele of the HDAC1
locus were cut into several pieces and blood cells were removed by centrifugation.
Remaining tissue was dissolved by a mixture of Pancreatin and Collagenase II to
obtain separation of cells. Cardiac cells were mixed with ESC AB2.2 cells in a 1:1
ratio and grown on feeder cells for 10 passages according to a 3T3 protocol what
says that cells are splitted 1:3 every third day onto new feeder cells. Feeder cells
are mitotically inactivated SNL76/7 fibroblasts expressing LIF and are resistant to
neomycin. After the enrichment of putative progenitor cells, cells were exposed to
G418, a neomycin analogon to get rid of ESC AB2.2 cells. Selection proceeded for 10
days and surviving cells were repeatedly exposed to the selection marker. Finally
eleven subclones were maintained and frozen for storage (Figure 1.5, A).
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A different strategy was used for the isolation of somatic stem cells (SSCs) from
several tissues of neonatal and adult mice. Here single clones were obtained from
the brain, pancreas and heart of wildtype mice. Contrary to the first isolation
procedure, they worked with a negative selection marker, thymidine kinase carried
by ESC Tag3 cells. In general the two procedures are quite similar, except the nega-
tive selection with Ganciclovir for 2x4 days instead of G481 for 10 days (Figure 1.5, B).
Figure 1.5: Two different procedures for the isolation of progenitor cells. Figure A
indicates the isolation of so called cardiovascular progenitor cells (CVPCs) by positive
selection of neomycin resistance gene. In contrast, for the isolation of so called somatic
stem cells (SSCs) from different tissues they selected for tk- neo- cells (B).
1.7 MAPK PATHWAY
The mitogen-activated protein kinase (MAPK) cascade seems to control both cell
proliferation and differentiation by induction by diverse growth factors and other
signals. This cascade consists of several membranal signaling molecules that transmit
extracellular signals to diverse cytoplasmic protein kinases. Finally, the signal reaches
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the nucleus and activates genes that regulate cellular processes such as proliferation,
differentiation and development. The process of transmission of extracellular signals
to their intracellular targets is driven by interacting proteins that build up a network
leading to serial responses. The signaling process is mediated by receptors, effector
molecules and of course by a cascade of kinases. Molecules, such as small GTP
binding protein (RAS), adapter molecules (GRB2) and guanine nucleotide exchange
factor (SOS) play a critical role in transmitting growth factor signals to the kinases.
The subsequent activation of this MAPK signaling cascade results in stimulation of
regulatory molecules that in turn initiates cellular processes. But this distinct signal-
ing cascade is not only one restricted pathway. Other pathways are able to use diverse
signaling molecules within this MAPK cascade or even can activate this pathway.
Diverse phosphorylation processes play a critical role in transmitting the extracellular
signals. Starting with phosphorylation events of tyrosyl residues during receptor
activation, the pathway is followed and ended by seryl and threonyl phosphorylations
of cytoplasmic and nuclear proteins. One of the first kinases that lie upstream of
the pathway is named Raf-1. Raf-1 is a serine/threonine kinase activated by various
mitogens and directly by RAS. Upon activation Raf-1 gets hyperphosphorylated
and in turn phosphorylates MAPKK (MEK-1) on a serine residue that activates
MEK-1. Full activation of MEK-1 results in activation of MAPK (ERK-1/2). ERK-1
and ERK-2 are highly conserved and differ only in their substrate specificity. Upon
activation threonine and tyrosine residues get phosphorylated (Seger and Krebs, 1995).
Inhibition of MAP kinase pathway by inhibition by SB203580 lead to a reduction
of cardiomyogenesis by decreasing the occurrence of cardiomyocytes in P19 cells,
while by inhibition of ERK1/2 by PD98059 no effect was visible. Expression levels of
mesodermal markers were decreased by SB203580 inhibition (Davidson and Morange,
2000). PD098059 is a synthetic inhibitor of the MAPK pathway by inhibition of
MAPK (MEK). This inhibitor is able to cross cell membranes and inhibits MAPK
activity through an allosteric mechanism without disturbing other kinase activities.
The inhibition by allosteric mechanism explains the selectivity for MEK kinase
(Dudley et al., 1995).
2 RATIONAL
Because cardiovascular diseases are quite common in present days and have fatal
impact of life quality or can even lead to death, it is important to develop adequate
therapies to inhibit such disruptions or find mechanisms that are able to stimulate
healing. A heart failure results in a dramatic reduction of cardiomyocytes what finally
can lead to organ destruction. Great hope lies in a new therapeutic option, myocardial
regeneration where injured tissues get replaced by endogenous or exogenous cells
to improve heart function. Though we know today that cardiomyocytes are able
to reenter mitosis after a myocardial infarct and that stem cells migrate to injured
tissues, this self-repair mechanism of the heart is not sufficient to substitute the loss
of cells. Thus, an exogenous source has to be found to completely replace injured
tissues and restore proper function of the diseased myocardium. Studies with stem
cells showed that they possess a great potential to push myocardial regeneration. In-
vestigations of intrinsic and extrinsic conditions to cultivate and differentiate somatic
progenitor cells will contribute to understand the molecular mechanisms that initiate
cardiomyogenesis and may help to rescue injured myocardium. The establishment of
a proper workflow to isolate progenitor cells will improve the understanding of such
mechanisms.
Here we isolated somatic progenitor cells from organs of the mouse, especially from
the heart. Today the focus lies in the characterization of these cells, their behavior in
culture and their differentiation potential. We determine optimal conditions to drive
differentiation to cardiomyocytes to be some day able to isolate human progenitor
cells and to differentiate them to cell types residing in the heart.
This diploma thesis deals with the detailed characterization of CVPCs as well as
the characterization of SSCs by FACS analysis and confocal immunofluorescence
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microscopy. We learned about their spontaneous differentiation potential to generate
limited cell types and investigated their behavior in commitment decision in the
presence of retinoic acid. Further we analyzed factors that may play important roles
affecting cardiomyogenesis by determining the Nkx2.5 gene expression with FACS
analysis and Luciferase assays.
3 ABBREVIATION
Alk3 bone morphogenetic protein receptor, type IA
BMP2 bone morphogenetic protein 2
c-kit Kit Oncogene
CMC cardiomyocyte
CMG cardiomyogenesis
cTnT cardiac Troponin T
CVD cardiovascular disease
CVPC cardiovascular progenitor cell
cDNA complementary deoxyribonucleic acid
CD31 cluster of differentiation molecule 31
DMEM dulbecco’s modified eagle medium
DMSO dimethylsulfoxid
dNTP deoxy nucleotide triphosphate
EB embryoid body
EDTA ethylenediaminetetraacetic acid
EGFP Enhanced Green Fluorescence Protein
ERK1/2 mitogen activated protein kinase 1
ESC embryonic stem cell
ETC endothelial cells
FACS Fluorescence Activated Cell Sorting
FOXA2 Forkhead Box
GATA4 GATA-binding protein 4
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GFAP glial fibrillary protein
HDAC Histone Deacetylase
He2 He2P11K13/5
Hi2 Hi2P11K15/6
IF immunofluorescence
ILK integrin linked kinase
Continued on next page
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20 3 ABBREVIATION
Isl 1 Islet-1
LIF leukemia inhibitory factor
MAPK mitogen activated protein kinase
MEF2C myocyte enhancer factor 2c
MEK1 mitogen activated protein kinase 2
Mesp1 mesoderm posterior 1
MHC-alpha myosin heavy chain-alpha
mRNA messenger Ribonucleic Acid
neo neomycin
nkx2.5 NK2 transcription factor related, locus 5
Oct3/4 octamer-binding transcription factor 3/4
PCR polymerase chain reaction
RA retinoic acid
RT-PCR reverse transcription polymerase chain reaction
Sca-1 stem cel antigen-1
SMA smooth muscle actin
Smad mothers against decapentaplegic homolog
SMC smooth muscle cell
Sox2 SRY-related box 2
SPARC Secreted Protein Acidic and Rich in Cystein
SSC somatic stem cell
STAT3 signal transducer and activator of transcription 3
tbx5 T box family
TGF-beta transforming growth factor-beta
tk thymidine kinase
TU-20 beta3-tubulin
vWF von Willebrand factor
4 RESULTS
4.1 CHARACTERISATION OF CARDIOVASCULAR PROGENITOR CELLS AND
SOMATIC STEM CELLS
Progenitor cell lines, called CVPCs (cardiovascular progenitor cells) and SSCs (so-
matic stem cells) have been previous isolated from our lab by two different but quite
similar methods. Both methods mimicked artificial niches consisting of LIF-producing
feeder cells and embryonic stem cells for the successful isolation and cultivation of
these progenitor cells. The two procedures differed mainly by their selection method.
For the isolation of CVPC a positive selection of neoR progenitor cells was performed,
while in the case of SSCs a negative selection for tk-neo- clones was done.
In the recent years focus was on the characterization of these cell lines. Most experi-
ments were performed on CVPCs, the first progenitor cell line isolated by our lab. So
far, self renewal and differentiation potential were investigated with interesting results.
To maintain their self-renewing potential and to keep cells in an undifferentiated
state cells were cultured on LIF-producing feeder layers (Hoebaus, 2009). CVPCs
could be already cultured to passage 66 without losing their self-renewal. During this
diploma thesis we even reached a passage of 111. Accordingly to Cartwright (2005)
embryonic stem cells need LIF/STAT3-dependent signaling pathway to maintain
their self-renewal and pluripotency. Same effect was seen in CVPCs. Western blot
analysis further showed STAT3 activity (Hoebaus, 2009). To test if CVPCs feature
pluripotency they were induced to differentiate. Finally, differentiation studies as
monolyer cultures were performed resulting in a restricted differentiation potential.
While embryonic stem cells are able to differentiate to any cell types of the body
(Desbaillets et al., 2000), stem cells are restricted to their tissue-lineage. CVPCs were
isolated from hearts and consequently are assumed to be restricted to the cardiac
lineage. Thus, stem cells and the CVPC line are quite similar. Today it is known
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that three transcriptional factors are involved in maintaining pluripotency of stem
cells as previously mentioned. One of these transcription factors is Oct3/4 which has
to be expressed in a critical amount, while differences lead to diverse differentiation
programs (Niwa et al., 2000). Similarly to stem cells, CVPCs express Oct3/4 indicat-
ing the ability for self-renewal (Hoebaus, 2009). In summary, CVPCs act like stem
cells in vitro. They possess a self-renewal potential proved by maintaining them in an
undifferentiated state over several passages without changing their morphology and
by STAT3 activity. Further they spontaneously differentiated only to cells residing in
the heart indicating a tissue-specific differentiation potential.
The other cell lines were called somatic stem cells (SSCs) and were isolated from
different organs of the mouse (heart, brain). So far, no morphological changes
were observed during cultivation on LIF-producing feeder cells. Not much is known
concerning differentiation potential and expression profiles.
4.1.1 Differentiation of ESCs in Embryoid Bodies
Embryonic stem cells have unique features that make them conceptually attractive for
cell therapy. Beside their ability of unlimited self-renewal they spontaneaously differ-
entiate into various cell types of the organism (He et al., 2009; Desbaillets et al., 2000).
For differentiation of ESCs we made use of the creation of embryoid bodies. Several
protocols are available for the aggregation of ESCs that are in general quite similar
with few differences (Desbaillets et al., 2000). Our lab optimized its own aggregate
procedure to the minutest detail. We apply here a protocol where hanging drops
were used for aggregate formation thereby we focused on the creation of conditions
adequate for CVPC aggregation. This protocol was used for all cell lines mentioned
in this diploma thesis to ensure same culture conditions.
Embryoid bodies are suited for the investigation of early developmental stages in vitro
because of their potential to mimic post-implantation embryonic development. The
embryoid bodies had a regular sized morphology and when attached to the surface
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cells start to spread into the periphery. ESC AB2.2 cell-derived embryoid bodies were
able among other cell types to differentiate into neuronal cells and functional skeletal
muscle cells (Figure 4.1). Neuronal cells were distinguished by their elongated, thin
and branched tubes (presumably neurites) emerging from the cell bodies. Skeletal
muscle cells were marked by contracting pipe-like structures consisting of fused cells.
Both were seen mainly in the periphery of the aggregates and were quite rare.
Figure 4.1: Infrequent differentiation of AB2.2 ESC into neuronal cells (A) and skeletal
muscle cells (B). AB2.2 ESCs were induced to differentiate in hanging drop cultures. On
day 5 of cultivation drops were rinsed onto gelatin-coated plates. Structural changes
were checked daily. A: Rare occurrence rate of neuron-like cells seen around day 16 of
cultivation. B: Contracting skeletal muscle cells were even more infrequently seen during
aggregate development (day 20), (bar=200µm, light microscope).
Frequently, we observed structures like beating cardiomyocytes, smooth muscle cells
and endothelial-like cells. But also fibroblast-like cells and hepatocyte cells were
observed.
4.1.2 Differentiation of CVPCs and SSCs in Embryoid Body-like Aggregates
CVPCs and SSCs grown in the presence of LIF-producing feeder cells maintain
their self-renewing potential and can be kept in an undifferentiated state for several
passages. By transferring cells onto gelatin-coated plates they started to differentiate
due to the absence of feeder cells. Cells lost their round shape and their ability
to form dense and tight colonies. They appeared angular and formed clusters of
differentiated cell aggregates. During differentiation as monolayers cell types like
cardiomyocytes, smooth muscle cells and endothelial cells were observed, but the
number varied highly between experiments and in general formation seemed to be
chaotic (Hoebaus, 2009).
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To control differentiation in a more effective extent we applied the well known
embryoid body system to our isolated precursor cells. This procedure resembles in
vivo conditions and mimics early embryonic developmental stages. An adequate
concentration of cells (4.5 x 104cells/ml) were dropped onto the lid of a dish and
were cultured as hanging drops for a period of five days. During this time period
cells start to divide and to form aggregates floating in the drops. The absence of
a surface to attach resembles perfectly in vivo conditions. On day five aggregates
were rinsed onto gelatin-coated culture dish plates and aggregates started to adhere
at the dish surface (Figure 4.2). Medium was changed according to a well adapted
feeding protocol in which the medium was changed every third day. To avoid sudden
absence of important factors secreted into the medium from the cells themselves, a
part of the old medium was always kept and fresh medium was added to ensure new
nutrients available in the media.
Figure 4.2: Schematic draw of embryoid body-like aggregate generation. Cells were
separated from feeder cells to prevent disruption of aggregate formation. Cells were
dropped onto the lid of a petri dish with a concentration of 900 cells/20µl. On day 5
hanging drops were rinsed onto gelatin-coated culture plates. For further cultivation
aggregates were fed every third day.
During cultivation aggregates started to differentiate and expanded into the periphery.
Three cell types residing in the heart were observed in the course of differentiation:
rhythmically contracting cardiomyocytes, slowly contracting smooth muscle cells and
endothelium-like cells.
4.1.3 Characterization of Cardiovascular Progenitor Cells (CVPCs)
This topic deals with the differences between differentiated CVPCs and AB2.2 ESCs
in aggregate size and morphology as well as the generation of distinct cell types.
4 RESULTS 25
Further attention was made on the restricted differentiation potential of CVPC to
the cardiac lineage and the differences of cardiomyocyte formation between CVPC
clones.
CVPCs - Size and Morphology Characterization
AB2.2 embryoid bodies tended to form horse-shoe like structures after attachment
to surface, while aggregated CVPCs seemed to have no such defined morphological
structure. CVPC aggregates comprised of cells densely arranged in the middle of the
aggregates, which were so compact that they appeared as dark circle in the brightfield
microscope (Figure 4.3, white arrows). This compact dark core was also seen in
AB2.2 aggregates, but here they were often not centered as seen in CVPC aggregates.
This dark core of CVPC aggregates was always surrounded by less dense cell areas
arranged as a ring around the core. The outer region was comprised by cells diffusible
arranged and spread further into periphery. In general CVPC aggregates were larger
and cell spreading into periphery proceeded faster compared to embryoid bodies.
Figure 4.3: Size and aggregate morphology of CVPC aggregates. Size and morphology
of CVPC clone A5 and H3 aggregates compared to AB2.2 embryoid body on day 9 of
cultivation. Aggregates consisted of a dense inner core, surrounded by less dense cell
areas reaching far into periphery. White arrows indicate the compact core, which was
centered in CVPC aggregates but not in embryoid bodies (bar=300µm).
CVPC aggregates possessed an inner cell mass of round shaped cells quite dense
arranged in the middle of the aggregate. This dense center was surrounded by a less
dense intermediate region comprising of differentiated cells. These differentiated cells
were characterized by their different cell morphology and elongated further out of
the dense center into periphery. Differentiated cells adjacent to and surrounding the
dense core, were round or angular shaped and not as densely packed as seen in the
core center (Figure 4.4, B, white arrow). The periphery was populated by elongated
angular shaped cells (Figure 4.4, C, white dashed arrow).
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Figure 4.4: Cell morphology characterization of CVPC aggregates. A: CVPC clone A5
(d12) consisting of a dense center bordered by the intermediate region which elongates
into the outer region. B and C: Intermediate region, comprising of round and angular
shaped cells (B, white arrow) and outer region populated mostly by elongated cells (C,
dashed,white arrow)(bar=50µm).
CVPCs - Differentiation Potential
Cardiac lineage commitment of CVPCs was initially assessed by previous studies that
revealed that CVPC aggregates differentiate spontaneously into cell types residing in
the heart (Hoebaus, 2009). In further differentiation studies we analyzed the potential
of CVPC aggregates to differentiate into other cell types not specific for the cardiac
lineage. By previous investigations of aggregate development and immunofluorescence
experiments we already know that CVPCs are able to differentiate spontaneously
into rhythmically beating cardiomyocytes, slowly contracting smooth muscle cells and
endothelial-like cells. To exclude differentiation into other lineages we stained CVPC
aggregates with antibodies specific for distinct cell types and performed confocal
scanning immunofluorescence microscopy and quantitative FACS analysis. Stainings
were done with a subset of markers specific for ectoderm, endoderm and mesoderm.
Ectodermal markers were provided by both anti-beta3- tubulin and anti-glial fibril-
lary protein (GFAP) antibodies. Both markers are specific for the neuronal lineage
and stain neuronal or glia cells, respectively. For determining cells positive for the
endodermal lineage we used anti-FOXA2 and anti- von Willebrand factor (vWF)
antibodies. FOXA2 is a member of the forkhead class of DNA-binding proteins and
are transcriptional activators for liver-specific transcripts regulating differentiation of
4 RESULTS 27
the pancreas and liver. The glycoprotein vWF (also Factor VIII) is produced mainly
by endothelial cells and is thereby secreted into the plasma or stored in intracellular
granules. It plays an important role in the blood coagulation system and is found
in platelet vessel walls. Mesodermal cells were proved by staining with anti-cardiac
troponin T (cTnT) and anti-smooth muscle actin (SMA) antibodies.
First, we performed confocal scanning immunofluorescence microscopy with antibodies
mentioned above. Therefore we made hanging drop cultures of CVPC clones A5 and
H3 and rinsed the aggregates on day 5 onto gelled cover slips and let them grow for
further eight days. After this cultivation time aggregates were stained with primary
antibodies specific for cell types of the endodermal, ectodermal and endodermal
lineage. Addition of fluorescently labeled secondary antibodies (anti-mouse Alexa
Fluor 488 and anti-rabbit Alexa Fluor 647) for indirect immunofluorescence was
followed. Neither ectodermal cells (beta3-tubulin+ and GFAP+ cells) nor FOXA2
-expressing cells were observed on day 13 of aggregate development. But we obtained
vWF-positive cells (Figure 4.5).
Figure 4.5: Immunofluorescence staining of CVPC aggregates on day 13 of cultivation.
Aggregates of CVPC clones A5 and H3 were made and grown onto gelled cover slips until
day 13. On day 13 aggregates were stained with primary antibodies against beta3-tubulin,
GFAP, FOXA2 and vWF. Secondary antibody staining was followed by either anti-mouse
Alexa Fluor 488 (beta3-tubulin) or anti-rabbit Alexa Fluor 647 (GFAP, FOXA2, vWF).
(bar = 500µm; LSM-Meta 510 confocal microscope).
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Both cardiac marker genes (cTnT, SMA) were expressed by cells of CVPC aggregates.
SMA positive cells were circular arranged thereby surrounding the compact center of
the aggregates. Presumably these cells represent myofibroblasts. Myofibroblasts have
features of both fibroblasts and smooth muscle cells. Cells expressing cTnT were
observed near the center of aggregates. While SMA positive cells were exclusively
seen in the outer region, cTnT positive cells resided in the intermediate region. Cells
expressing cTnT appeared in clusters and were rarely observed individually, they
tended to be in groups (Figure 4.6).
Figure 4.6: Immunofluorescence staining of CVPC aggregates with cardiac markers.
Again embryoid body-like aggregates were generated and stained with anti-cTnT and
anti-SMA antibodies. Secondary antibody staining was followed by anti-mouse Alexa
Fluor 488 (bar = 200µm; LSM-Meta 510 confocal microscope).
Next we analyzed the cell population of CVPC clone A5 and H3 aggregates with
quantitative FACS analysis. With this method we wanted to determine the incidence
of each cell type mentioned above among a cell population of A5 and H3 aggregates.
For FACS analysis aggregates grown on gelatin-coated culture plates were detached
from the gelatin-layer and separated into individually cells by trypsinization on day
13. This cell suspension was then fixed with paraformaldehyde and stained with same
antibodies used during immunofluorescence microscopy. Surprisingly, the frequency
rates of the investigated cell types were enormous and quite different to data obtained
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during immunofluorescence microscopy. Therefore, data received by FACS analysis
were not reliable due to this great divergence. Figure 4.7 indicates the percentage of
cell populations in CVPC clone A5 and H3 aggregates. Beta3-tubulin positive cells
were absent in A5 and very low in H3 aggregates. The frequency of GFAP-expressing
cells was extremely high with 87.47% in A5 and 51.79% in H3 aggregates, although
immunofluorescence microscopy indicated an absence of these ectodermal cell type.
Similarly, FACS analysis revealed a presence of FOXA2-expressing cells (A5: 2.51%,
H3: 0.97%), while they were also absent during immunofluorescence microscopy.
Frequency rate of vWF-expressing cells was nearly 100% during FACS analysis and
only few cTnT positive cells (0.49%) could be observed in A5 cell population, whereas
H3 aggregates possessed 0.065% cTnT-expressing cells. SMA-expressing cells were
seen in both A5 and H3 aggregates. A5 aggregates featured 88.77% SMA positive
cells, while H3 aggregates only 48.99%.
Figure 4.7: Percental distribution of cell types emerging in A5 and H3 aggregates on
day 13 of cultivation. Aggregates were separated into single-cell suspensions, fixed with
paraformaldehyde and stained with antibodies against beta3-tubulin, GFAP, FOXA2,
vWF, SMA and cTnT. Secondary antibody staining was followed by either anti-mouse
Alexa Fluor 488 (beta3-tubulin, SMA, cTnT) or anti-rabbit Alexa Fluor 647 (GFAP,
FOXA2, vWF)(FACS Calibur).
As already mentioned, data obtained during immunofluorescence studies and data
received from FACS analysis were very contradictorily. Cells expressing FOXA2,
beta3-tubulin and GFAP were absolutely absent by investigating cover slips under
the confocal microscope. While FACS analysis showed extremely high values for
the occurrence rate of vWF and GFAP expressing cells. In the assumption that the
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error is always the same among the data received from FACS analysis we decided
that it might be possible to compare the occurrence rate of CVPCs with AB2.2
cell population to obtain at least an idea how CVPC aggregates differ from AB2.2
aggregates (Figure 4.8). We did not compare data received from staining with anti-
FOXA2, anti-GFAP and anti-beta3-tubulin antibodies, because no positive signals
were seen during immunofluorescence microscopy.
Figure 4.8: Comparison of CVPC and ESC AB2.2 aggregates on day 13. Data of
CVPCs obtained from FACS analysis were divided through AB2.2 data. The value 1
represents the baseline of AB2.2 data (red). Data above this baseline mean a higher
occurrence rate of this cell type compared to AB2.2 and below the opposite.
We can clearly see that CVPC clone A5 showed a higher number of cTnT- and
SMA-expressing cells compared to AB2.2 aggregates. In contrast clone H3 revealed a
lower occurrence rate of these cell types. But vWF expression was nearly the same
as seen in AB2.2 cell population (Figure 4.8).
We also performed FACS analysis with undifferentiated CVPC clone A5 and H3
aggregates as well as ESC AB2.2 aggregates. Therefore cells were grown on LIF-
expressing feeder cells to keep them in an undifferentiated state. For FACS analysis
cells were trypsinized, fixed in 4% paraformaldehyde and stained with same antibodies
used in previous experiments. To compare the composition of cell populations
between the undifferentiated and differentated state we divided data obtained from
analyzing CVPC aggregates by data received from undifferentiated cells. While
vWF expression was not changed dramatically during differentiation of CVPC and
ESC aggregates, other marker showed changes in their expression profiles upon
differentiation. Undifferentiated AB2.2 cells showed a high expression level of beta3-
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tubulin reaching nearly 100% while CVPC clones only reached about 50% (not
shown). In general, during aggregate development neuronal differentiation is strongly
reduced as seen with GFAP and with beta3-tubulin (TU-20). Expression of cTnT
was reduced in differentiated AB2.2 and H3 cells. Data from A5 cells are missing
due to the fact that a division through 0 is not possible. So differentiated A5 cells
showed a higher cTnT expression compared to undifferentiated cells. SMA expression
was reduced during aggregate development in AB2.2 and CVPC aggregates. Also
FOXA2 expression was reduced upon differentiation in AB2.2 and H3 cells, but was
increased in differentiated A5 cells (Figure 4.9).
Figure 4.9: Comparison of cell populations of CVPC aggregates and undifferentiated
cells. Data received from analyzing CVPC aggregates are divided by data of undifferen-
tiated cells. Value 1 represents the baseline of undifferentiated cells (red). Data above
this baseline mean a higher expression of markers in differentiated cells compared to
undifferentiated cells and below the opposite.
CVPCs - Cardiomyocyte Development
Not only a divergence between AB2.2 ESC and CVPC aggregate morphology was
observed, but also beating efficiency and onset of cardiomyocyte formation was
different in AB2.2 ESC and CVPCs and even among CVPC clones. Although CVPC
clones originate from the same clone, they vary among themselves. This was indicated
by unequal mRNA expression profiles (Hoebaus, 2009) and different beating capacity
of cardiomyocytes. Already in early days of aggregate development first differences
in beating capacity were seen among these cell lines. First cardiomyocytes in AB2.2
aggregates started to beat around day 8 and rapidly reached almost hundred percent,
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whereas beating cardiomyocytes in A5 aggregates were not seen until day 11. And
CVPC clone H3 hardly ever showed beating cardiomyocytes (Figure 4.10).
Figure 4.10: Cardiomyogenesis in CVPC clone aggregates. Aggregates of CVPC
clones A5, H3 and ESC AB2.2 aggregates were made and the appearance of beating
cardiomyocytes was checked every day. Data are means of 40 counted aggregates from 4
culture plates (10 counts per culture plate).
All in all, we could see that cardiomyogenesis was delayed in CVPC clones. But
cardiomyocytes maintained their beating capacity over a longer time period in
CVPC A5 aggregates, while they already started to disappear in AB2.2 aggregates
(Gottschamel, 2010). The low occurrence rate of beating cardiomyocytes in H3
aggregates go along with data seen in FACS analysis where cTnT expressing cells
were nearly absent (Figure 4.7).
4.1.4 Characterization of Somatic Stem Cells (SSCs)
SSCs - Size and Morphology Characterization
SSC clone Hi2P11K15/6 was isolated from the brain of two day old mice, while
He2P11K13/5 from the heart. Aggregates of SSC clones (Hi2P11K15/6, He2P11K13/5)
featured also different morphological structures compared to embryoid bodies. They
were much larger as AB2.2 aggregates and even larger as CVPC aggregates. SSC clone
He2P11K13/5 aggregates mostly seemed to have a cell cluster that radiated from the
center of the aggregate to the periphery. While the inner cell mass of CVPC clones
is round shaped, He2P11K13/5 aggregates often had a stellar shaped core. Often
we observed in He2P11K13/5 aggregates a defined edge in contrast to Hi2P11K15/6
and CVPC aggregates where there was a continuous transition of cells moving from
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the center to the periphery. But sometimes we could also see no such structural
separation in He2P11K13/5 aggregates and then they possessed similar structural
morphologies as seen in Hi2P11K15/6 aggregates. Hi2P11K15/6 aggregates had a
diffuse structure comprising of a core of dense cells, which was infrequently seen in
the center of the aggregate but rather was located out of the middle. In the less
dense areas often gaps of cells were observed (Figure 4.11). SSC clone He2P11K13/5
aggregates often possessed more elongated cells in the intermediate region while SSC
clone Hi2P11K15/6 and CVPC clones showed a higher number of round and angular
shaped cells. As seen in CVPC clones both SSC clone aggregates featured mostly
elongated cells in the outer region (Figure 4.11,B).
Figure 4.11: Morphological differences between ESC AB2.2 and SSC aggregates.
Aggregate morphology of AB2.2 and SSC clones He2P11K13/5 and Hi2P11K15/6
aggregates on day 9 of cultivation. A and B: Intermediate region of SSC clone aggregates
on day 12 of cultivation (bar=200µm).
SSCs - Differentiation Potential
SSC clone aggregates not only differed in size and morphology from CVPC clones,
their differentiation potential seemed not as restricted to the cardiac lineage as seen
in CVPC clones. While aggregates of CVPC clones spontaneously differentiated
only to cells residing in the heart, SSC clone aggregates possessed also cells from
other lineages. Rarely, we could see cells with structures reminding of neuronal cells
(Figure 4.12).
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Figure 4.12: Neuronal differentiation in aggregates of SSC clones He2P11K13/5 (A)
and Hi2P11K15/6 (B). Outer region of aggregates (d17) comprising neuron-like cells
possessing a cell body with neurites. White circles indicate presence of neuron-like cells
(bar=100µm).
Because of the isolation of Hi2P11K15/6 from the murine brain we expected a
tendency to neuronal differentiation and therefore we were not surprised by the
appearance of neuron-like cells. Whereas we did not expected the presence of neuron-
like cells in SSC clone He2P11K13/5 cells. Because of the ability of spontaneous
neuronal differentiation in He2P11K13/5 cells we concluded that these cells were not
restricted to the cardiac lineage as seen in CVPC clones, although they were isolated
from the murine heart too.
Here, we also performed differentiation studies to investigate lineage commitment
of SSC clones. Same experiments and conditions were used as already described in
differentiation studies with CVPC clones. We analyzed appearance of cells expressing
beta3-tubulin, GFAP, FOXA2, vWF, SMA and cTnT with immunofluorescence mi-
croscopy and determined their incidence in the cell population of SSC aggregates with
FACS analysis. Again, primary antibodies against beta3-tubulin, GFAP, FOXA2,
vWF, SMA and cTnT and secondary antibodies anti-mouse Alexa Fluor 488 and anti-
rabbit Alexa Fluor 647 were used. Aggregates of He2P11K13/5 and Hi2P11K15/6
(d13) were prepared for FACS analysis or immunofluorescence microscopy, respectively.
Aggregates of Hi2P11K15/6 and He2P11K13/5 revealed already the presence of
neuron-like cells by investigations under the light microscope. Indeed, FACS anal-
ysis proved the appearance of beta3-tubulin expressing cells in Hi2P11K15/6 with
7.14% (Figure 4.13), but IF studies showed no positive fluorescence signal (not shown).
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Figure 4.13: Occurrence or absence of diverse cell types in cell populations of SSC
clones He2P11K13/5 and Hi2P11K15/6. A-D: Immunofluorescence microscopy of SSC
aggregates on day 13 with primary anti-cTnT, SMA and vWF and secondary anti-mouse
Alexa Fluor 488 (cTnT, SMA) and anti-rabbit Alexa Fluor 647 (vWF) antibodies, respec-
tively (bar= 200µm). E: Quantitative FACS analysis of He2P11K13/5, Hi2P11K15/6 and
AB2.2 aggregates on day 13 of cultivation. Chart represents the percental distribution
of beta3-tubulin expressing cells in the cell population of aggregates as indicated.
Although we classified the neuron-like cells seen in He2P11K13/5 aggregates dur-
ing investigation under the light microscope as neurons we were not able to prove
the presence of such cells with anti-beta3-tubulin antibodies. In general, SSC ag-
gregates (d13) complied with CVPC aggregates in their differentiation potential.
Immunofluorescence microscopy showed no positive signals for the ectodermal markers
beta3-tubulin and GFAP. Further only vWF expressing cells were recognized, while
FOXA2 positive cells were absent. SMA positive cells were observed in the same
arrangement and in a more or less similar extent as seen in immunofluorescence
studies with CVPC aggregates. He2P11K13/5 aggregates possessed cTnT-expressing
cells, while Hi2P11K15/6 aggregates were the only cell line that lacks this cell type.
This indicates a decreased potential or even a prevention of cardiomyogenesis in
Hi2P11K15/6 cells isolated from the murine brain.
In SSC aggregates (d13), the same discrepancy between data received from immunoflu-
orescence microscopy and FACS analysis was observed as seen in experiments with
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CVPC aggregates. Percentage of markers like vWF, GFAP and SMA obtained during
FACS analysis were extremely high, ranging from 70% to nearly 100% (not shown),
but this was contrary to results received from immunofluorescence microscopy. There
we could indeed prove the presence of vWF and SMA-expressing cells, but they were
not as prevalent as quantitative FACS analysis revealed. For GFAP actually, we
even could not obtain one single positive signal for GFAP during immunofluores-
cence studies. Interestingly, we could observe a higher number of FOXA2 expressing
cells (ranging from 10-15%) and of beta3-tubulin expressing cells in Hi2P11K15/6
aggregates during FACS analysis what indicated differences to CVPC aggregates.
Again we decided to compare the expression relation of SSC aggregates with ESC
aggregates. By comparing expression levels of SSC aggregates to ESC aggregates we
could see few differences in SMA, GFAP and vWF. FOXA2 expressing cells were higher
in both He2P11K13/5 and Hi2P11K15/6 than in ESC aggregates. In Hi2P11K15/6
cell population we recognized a higher number of cTnT and beta3-tubulin (TU-20)
expressing cells compared to He2P11K13/5 aggregates (Figure 4.14).
Figure 4.14: Expression relation of differentiated SSC clones to differentiated ESC.
Data of SSC aggregates on day 13 obtained from FACS analysis were divided through
ESC data (A, B). The value 1 represents the baseline of AB2.2 data (red). Data above
this baseline mean a higher occurrence rate of this cell type compared to AB2.2 and
below the opposite.
Next, we compared cell populations of differentiated SSC aggregates on day 13 to
undifferentiated SSCs (Figure 4.15). Upon differentiation a decline in the incidence of
cardiac (cTnT, SMA) and ectodermal markers (TU-20, GFAP) was observed, while
the frequency of vWF-expressing cells was to a greater or lesser extent maintained.
But the incidence of FOXA2-expressing cells in He2P11K13/5 cells rapidly increased
during differentiation.
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Figure 4.15: Comparison of cell populations of SSC aggregates (d13) and undifferenti-
ated SSCs. Data received from analyzing SSC aggregates on day 13 are divided by data
of undifferentiated cells. Again value 1 represents the baseline of undifferentiated cells
(red). Data above this baseline mean a higher expression of markers in differentiated
cells compared to undifferentiated cells and below the opposite.
Though immunofluorescence showed no presence of neuronal cells in Hi2P11K15/6,
we proved their appearance by investigation under the light microscope and FACS
analysis. So we assumed that Hi2P11K15/6 have a restriction to the neuronal
lineage. Whereas Hi2P11K15/6 cells showed a commitment to their tissue lineage
they were isolated from, He2P11K13/5 cells seemed to possess a less limited potential.
Because of their isolation from the murine heart we assumed He2P11K13/5 cells to
be restricted to the cardiac lineage, but morphology investigations under the light
microscope revealed an appearance of neuron-like cells which could however not been
confirmed by immunofluorescence and FACS analysis.
SSCs - Cardiomyocyte Development
Because SSC clone He2P11K13/5 cells were isolated from the murine heart we
expected a high occurrence rate of beating cardiomyocytes, instead we had to recognize
an absence of beating aggregates (Figure 4.16). We expected that Hi2P11K15/6 were
not able to undergo cardiomyogenesis due to the fact that they were isolated from the
murine brain. These results were confirmed by an absence of beating cardiomyocytes
(Figure 4.16) and a lack of cTnT-expressing cells observed during immunofluorescence
studies (Figure 4.13).
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Figure 4.16: Cardiomyogenesis in SSC clone aggregates. Aggregates of SSC clones
He2P11K13/5 and Hi2P11K15/6 as well as ESC AB2.2 aggregates were made and the
occurrence rate of beating cardiomyocytes was determined during aggregate development
(A) Data are means of 40 counted aggregates from 4 culture plates (10 counts per culture
plate). B: Presence of non-contracting cardiomyocytes in He2P11K13/5 aggregates on
day 26 of culitvation (see white arrows) (bar=50µm).
4.1.5 Induction of Neuronal Differentiation by Retinoic Acid
Retinoic acid is known to induce neuronal differentiation in mouse embryonic stem
cells, because ESC aggregates exposed to retinoic acid differentiated to neuron-like
cells (Bain et al., 1995). While gene expression of neuronal markers was enhanced
during retinoic acid induction, they could see a repression of mesodermal gene ex-
pression (Bain et al., 1996). But induction of neuronal differentiation is not simply
driven by exposure to retinoic acid alone, in fact it is dependent on its concentration.
Retinoic acid influences the commitment of embryonic stem cells in a dose-dependent
manner. Teratocarcinoma cells exposed to low concentrations of retinoic acid (10−9
M) are driven to the cardiac differentiation, while high concentrations ranging from
10−7 to 10−5 M resulted in the formation of neurons and glia cells (Edwards and
McBurney, 1983).
Though we already had proven that CVPCs are restricted to the cardiac lineage and
could only differentiate spontaneously into cells residing in the heart we wanted to
investigate whether cells are capable to give rise to cell types of other lineages. Here,
we tested the influence of high concentrations of retinoic acid on the differentiation
potential of CVPCs and SSCs.
AB2.2 ESC, CVPC and SSC aggregates were made and five days after cultivation as
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hanging drops they were rinsed onto gelatin-coated culture plates. Addition of retinoic
acid (5 x 10−7 M) to the aggregates started on day 5 of cultivation. Aggregates
were fed every third day and so retinoic acid was replaced by fresh one to ensure a
constant concentration present during the whole cultivation.
Effect of Retinoic Acid on Aggregate Morphology
Retinoic acid induction caused alterations in aggregate morphology indicating an
inhibiting influence on aggregate formation. First distinguishable morphological
differences between aggregates untreated and treated with retinoic acid were observed
already three days after rinsing the hanging drops onto gelatin-coated culture plates
(Figure 4.17). On day 8, treated aggregates were much smaller in size compared to
untreated ones. Cells in the middle of the aggregates maintained their round and
dense arrangement and did not expand into periphery. So the aggregates seemed
to be more compact and cell spreading into periphery was reduced compared to
untreated aggregates. The decreased cell spreading might be due to a reduced cell
differentiation.
Figure 4.17: Pictures of treated (first row) and untreated (second row) aggregates on
day 8 of cultivation. (bar=300µm, light microscope).
Effect of Retinoic Acid on Cardiomyogenesis
Due to the fact that retinoic acid induction impaired cell differentiation it is hardly
surprising that it also had an effect on cardiomyogenesis. Both SSC and CVPC
aggregates treated with retinoic acid developed cardiomyocytes to a lesser extend and
beating capacity was strongly reduced. Addition of retinoic acid from day 5 to day
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20 resulted in a reduction of cardiomyocyte formation and a decreased frequency of
beating aggregates in all cell lines, ESC (AB2.2), CVPC (clone A5) and SSC (clone
He2P11K13/5) (Figure 4.18; Figure 4.19).
Figure 4.18: Influence of retinoic acid on beating CVPC aggregates on day 13. CVPC
clone A5 and ESC AB2.2 cells were cultured as hanging drops for five days and were
rinsed onto gelled culture plates. From day 5 on aggregates were exposed to retinoic
acid (5x10−7 M) to induce neuronal differentiation. Beating efficiency of aggregates was
determined form day 5 to 20. Data are means of 4 independent experiments with 100
counted aggregates, each untreated and treated in summary.
Figure 4.19: Influence of retinoic acid on beating SSC aggregates.Data are means of 4
independent experiments with 120 counted aggregates, each untreated and treated in
summary.
Untreated aggregates possessed beating cells located mainly in the periphery which
were getting bigger during cultivation, compared to cardiomyocytes exposed to
retinoic acid. These cardiomyocytes hardly ever beat and the few beating ones were
located in the compact center and marginally increased in size. Interestingly, these
cardiomyocytes featured a higher beating frequency compared to untreated ones.
During our investigation on beating efficiency in retinoic acid-treated aggregates
we could recognize a correlation between aggregate size and the incidence of beat-
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ing cardiomyocytes. Indeed, treated aggregates were always smaller compared to
control, but aggregate size varied among treated aggregates. Aggregates that were
somewhat bigger as usual possessed more beating cardiomyocytes. The same effect
was observed for smooth muscle cells (not shown). They hardly contracted, were
more infrequently seen and formation was dependent on the size of treated aggregates.
Immunofluorescence studies revealed an absence of cTnT-expressing cells in retinoic
acid-treated aggregates (AB2.2, SSC, CVPC) on day 13 of cultivation (Figure 4.20,
A). These data confirmed the extremely low frequency of beating cardiomyocytes
observed during investigations on the beating capacity under the light microscope.
In summary, the presence of retinoic acid seemed to disrupt aggregate-expansion and
prevents cardiomyogenesis.
Figure 4.20: Immunofluorescence staining of SSC aggregates on day 13. Aggregates
were stained with cTnT antibody and secondary anti-mouse Alexa Fluor 488 antibody.
A: Immunofluorescence staining of He2P11K13/5 aggregates treated with retinoic acid
on day 13 of cultivation. B: Immunofluorescence staining of untreated He2P11K13/5
aggregates possessing cardiomyocytes (bar=00µm).
Effect of retinoic acid on Nkx2.5 gene expression
Further we tested the negative influence of retinoic acid on cardiomyogenesis by
FACS analysis. The stable A5-CSX cell line carries an EGFP reporter gene located
in the Nkx2.5 gene and is therefore a suitable tool for the investigation of the effect of
retinoic acid on cardiomyogenesis by FACS analysis. Undifferentiated A5-CSX (clone
2) cells were transferred onto gelatin-coated plates and retinoic acid was added for 3
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hours, 24 hours and 3 days. For control A5 cells not carrying the EGFP promoter
and A5-CSX cells not treated with retinoic acid were used (Figure 4.21).
Figure 4.21: FACS analysis of undifferentiated CVPC clone A5-CSX treated with
retinoic acid for 3h, 24h and 3d. A5 cells carrying an EGFP reporter gene were treated
with retinoic acid (5x10−7 M) for indicated time intervals. EGFP signal correlates with
the activation/repression of Nkx2.5 gene. FACS values were divided by mean value
of control (+EGFP) to compare the effect of retinoic acid among each time interval.
This division is necessary due to slight fluctuations in Nkx2.5 gene expression during
the indicated time intervals. Data are means of one experiment with duplicates. For
standard deviation see Appendix.
Retinoic acid induction reduced the Nkx2.5 expression. A continuous decline in the
EGFP expression was observed with greatest effect seen by adding retinoic acid for
three days.
We repeated the experiment with differentiated A5-CSX cells. For this A5-CSX cells
were aggregated in hanging drops using the embryoid body model. Aggregates were
rinsed onto gelatin-coated culture plates on day 5. On day 13 of cultivation retinoic
acid (5x10−7) was added for 3h and 24h (Figure 4.22). Aggregates were trypsinized
and prepared for FACS analysis.
Again a reduction in the Nkx2.5 gene expression was observed. While addition of
retinoic acid for 3h days resulted in a minimal significant reduction, the addition of
retinoic acid for 24 hours had a great effect.
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Figure 4.22: FACS analysis of differentiated CVPC clone A5-CSX (day 13) treated with
retinoic acid for 3h and 24h. A5 cells carrying an EGFP reporter gene were aggregated
in hanging drops and rinsed onto gelatin-coated plates. On day 13 of cultivation the
aggregates were treated with retinoic acid (5x10−7 M) for indicated time intervals. FACS
values were divided by mean value of control (+EGFP) to compare the effect of retinoic
acid among each time interval. This division is necessary due to slight fluctuations in
Nkx2.5 gene expression during aggregate development. Data are means of one experiment
with duplicates. For standard deviation see Appendix.
Morphology of Neuron-like Cells
An ordinary neuronal cell possesses a central spherical region often called soma or cell
body, where general cellular processes take place and it also consists of neurites that
enables this cell type to conduct information over long distances. Neurites (axons,
dendrites) are thin tubes that arise from the cell body and are the most obvious
difference to regular cells which makes neurons easily distinguishable to other cell
types.
Neuron-like cells observed in aggregates treated with retinoic acid resemble neurons of
the brain (Figure 4.23). The neuron-like cells observed during investigations under the
light microscope feature quite similar morphological characteristics, like a spherical
body and thin tubes arising from this central region. These thin tubes (presumably
neurites) often branch and some connect to other tubes to from very simple "networks".
Because the neuron-like cells share this typical neuronal characteristics we concluded
that upon retinoic acid induction the cells were driven to neuronal differentiation
thereby forming neuron-like cells.
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Figure 4.23: Morphological similarities between neuronal cells in the brain and neuron-
like cells observed during retinoic acid induction. As typical neurons the neuron-like
cells observed in treated aggregates possessed a cell body (indicated by red arrow) and
neurites (indicated by dashed arrows, black and white). White circle marks clusters of
neuron-like cells that presumably connect to each other (bar = 50µ).
Because neuron-like cells were never observed in the dense center of the aggregates, just
only in the periphery we concluded that neuronal differentiation proceeds exclusively
at the periphery of retinoic acid-treated aggregates. Usually, several thick tubes
radiated away from the aggregate center into the periphery over quite long distances
(Figure 4.24). The more common neuron-like cells located directly at the periphery
were in general not as thick as those arising from the aggregate center.
Figure 4.24: Pictures represent cuts of aggregates treated with retinoic acid on day 11.
All aggregates treated with retinoic acid possessed thick tubes arising from the center
into the periphery (A: AB2.2, B: CVPC, C: SSC)(bar=100µm).
Immunofluorescence studies of CVPC, SSC and ESC aggregates on day 13 exposed
to retinoic acid was performed to prove the presence of neuron-like cells with anti-
beta3-tubulin antibodies. Unfortunately, any positive signal for this neuronal marker
was absent (Figure 4.25, A). We could exclude a dysfunction of this antibody itself
as well as an incorrect staining procedure due to the ability of the anti-beta3-tubulin
antibody to recognize neuron-like cells in untreated AB2.2 aggregates on day 20.
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Therefore we can not confirm that the cells indicated as neuron-like cells were actually
neuronal cells, although investigations under the light microscope revealed neuron-like
phenotypical structures.
Figure 4.25: Immunofluorescence staining of SSC aggregate (He2P11K13/5) on day 13
treated with retinoic acid. Aggregates were stained with anti-beta3-tubulin antibodies
and with secondary antibodies Alexa Fluor 488 (A) or anti-mouse FITC (B), respectively.
Here, diverse secondary antibodies were used, but same results were achieved by using
identical secondary antibodies. A: He2P11K13/5 aggregate on day 13 treated with
retinoic acid. B: ESC aggregate on day 20 not exposed to retinoic acid. (LSM-Meta,
confocal microscope).
Occurrence of Neuron-like Cells
The appearance of neuron-like cells was checked every day from day 6 till day 20
during the cultivation of aggregates. Aggregated ESCs treated with retinoic acid
showed first appearance of neuron-like cells on day 9. The percentage of aggregates
possessing neuronal cells increased continuously and reached hundred percent within
the next five days. On day 14 of cultivation all ESC aggregates possessed neuron-like
cells, which were still seen on day 20. Though the initiation of neuronal differentiation
seemed to be stronger induced by retinoic acid in CVPC aggregates compared to ESC
aggregates, the incidence of aggregates possessing neuron-like cells fell continuously
in later developmental stages whereas ESC aggregates maintained their occurrence
rate. So the effect of retinoic acid did not hold on as long as seen in ESC aggregates.
Compared to ESC aggregates neuron-like cells seen in CVPC aggregates appeared one
to two days earlier, hardly never reached hundred percent and started to disappear
prior as to neuron-like cells seen in ESC aggregates (Figure 4.26, A).
46 4 RESULTS
Minor morphological differences between neuron-like cells seen in treated CVPC
aggregates and ESC aggregates were detected (Figure 4.26, B-D). While neuron-like
cells originated from CVPC clone A5 and H3 possessed quite similar structures, we
could distinguish them from neuron-like cells observed in ESC treated aggregates.
ESC derived neuron-like cells were often not as elongated as cells seen in treated
CVPC aggregates. Generally, they possessed shorter tubes radiating from the cell
body and tended to occur mainly in clusters compared to neuron-like cells in CVPC
aggregates that were often seen individually.
Figure 4.26: Percentage of neuron-like cells observed in CVPC aggregates treated
with retinoic acid. Retinoic acid was added from day 5 (5x10−7 M). A: Percentage
of aggregates possessing neuron-like cells was determined from day 6 to 20. First
appearance of neuron-like cells were observed on day 7 of CVPC clone A5, day 9 of
CVPC clones H3 as well as in AB2.2 ESC aggregates. Data are means of 3 independent
experiments with 80 counted aggregates (AB2.2, H3) and 2 experiments with 50 counts
in A5. B-D: Morphological differences of neuron-like cells in A5 (B), H3 (C) and AB2.2
(D) aggregates.
Determining the occurrence rate of retinoic acid-treated SSC aggregates possessing
neuron-like cells revealed similar results as obtained from studies with CVPC ag-
gregates. Also here, SSC aggregates showed a strong induction in the first days of
cultivation, while it fell in later developmental stages (Figure 4.27, A). Both treated
SSC clone aggregates featured neuron-like cells similar to that observed in treated
CVPC aggregates as well as those seen in ESC aggregates (Figure 4.27, B and C).
Though CVPCs and SSCs are able to be induced to differentiate to neuron-like cells
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Figure 4.27: Influence of retinoic acid on neuron-like cell formation in SSC aggregates
exposed to retinoic acid. SSC clones He2P11K13/5 and Hi2P11K15/6 aggregates formed
neuron-like cells after several days of exposure to retinoic acid. A: Percentage of aggregates
possessing neuron-like cells was determined from day 6 to 20. Percentage of neuron-like
cells was highest during days 10 to 13 and decreased in later developmental stages to
around 60%. Data are means of 3 independent experiments with 110 counted aggregates
(He2, Hi2). B-C: Morphological differences of neuron-like cells in He2P11K13/5 (B) and
Hi2P11K15/6 (C) aggregates.
by retinoic acid, without induction we could never observe spontaneous neuronal
differentiation, at least in CVPC aggregates. Untreated Hi2P11K15/6 aggregates
were supposed to differentiate to neuron-like cells, because of their isolation from the
murine brain. Because we could prove the presence of neuron-like cells in untreated
Hi2P11K15/6 aggregates we were able to confirm the assumption of these cells to have
a neuronal differentiation potential. Surprisingly, untreated He2P11K13/5 cells were
also able to differentiate to neuron-like cells without induction (Figure 4.28, A). So
without induction by retinoic acid CVPC aggregates were never driven into neuronal
differentiation, while AB2.2 ESC, He2P11K13/5 and Hi2P11K15/6 aggregates showed
even without induction neuron-like cell formation. The difference in neuron-like cells
occurrence rate of untreated and treated aggregates falls into place especially by
looking at figure 4.28,B.
Comparing phenotypical differences of neuron-like cells of treated and untreated SSC
aggregates revealed only minor differences (Figure 4.29). Great differences were only
seen by comparing neuron-like cells of untreated and treated AB2.2 aggregates. Here,
untreated neuron-like cells possessed thin tubes that arose from the center of the
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Figure 4.28: Percentage of neuron-like cells observed in untreated aggregates. A:
Percentage of aggregates possessing neuron-like cells was determined from day 6 to
25. First appearance of neuron-like cells were observed on day 9 (AB2.2), day 12
(He2P11K13/4) and day 15 (Hi2P11K15/6). CVPC clones never showed spontaneous
formation of neuron-like cells. B: Chart represents mean value of neuron-like cell frequency
between day 14 to 17 in untreated and retinoic acid-treated AB2.2, A5, He2P11K13/5
and Hi2P11K15/6 aggregates. Data are means of 3 experiments with 110 counts (He2,
Hi2), 3 experiments with 80 counts (AB2.2,H3) and 2 experiments with 50 counts for
A5.
aggregate and reached far into the periphery. Such morphological characteristics
could also be observed in treated AB2.2 aggregates, but here, the tubes seemed to be
much thicker. Whereas neuron-like cells could be also observed in the periphery of
treated aggregates, in untreated aggregates such cells were absent and neuron-like
cells exclusively originated from the center. As far as we can say, the only differences
in untreated and treated neuron-like cells in He2P11K13/5 was that in treated
aggregates neuron-like cells were widely distributed throughout the aggregate, while
in untreated aggregates the occurrence of neuron-like cells was mainly restricted to
one part of the aggregate. Neuron-like cells of untreated Hi2P11K15/6 aggregates
were often seen distributed over the whole aggregate and the tubes were often shorter
as compared to neuron-like cells in treated aggregates.
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Figure 4.29: Morphological differences of neuron-like cells in untreated and treated
AB2.2 and SSC aggregates on day 13 and 12 of cultivation. First row represent examples
of neuron-like cells observed in aggregates exposed to retinoic acid. Second row shows
neuron-like cells of untreated neuron-like cells.
Effect of retinoic acid on neuronal marker expression
Further we analyzed the expression level of neuronal markers in aggregated cells.
Therefore RNA of undifferentiated, untreated and treated aggregates on day 15 were
isolated and transcribed into cDNA. RT-PCR analysis was done with primer pairs for
tyrosine hydroxylase (TH) and glial fibrillary protein (GFAP) to prove the presence
of neuronal cells (Figure 4.30).
RT-PCR revealed that ESC AB2.2 possessed no TH-expressing cells whether in an
undifferentiated state or upon differentiation. Even in the presence of retinoic acid no
bands for TH were visible. But RA-treated AB2.2 aggregates revealed the presence
of GFAP expressing cells. CVPC clone A5 aggregates showed under RA exposure
tyrosine hydroxylase expression, but no GFAP expression, while in CVPC clone H3
aggregates the opposite effect was seen. Undifferentiated CVPC clone A5 possessed
no bands for both neuronal markers, in contrast to undifferentiated CVPC clone H3
that showed a pale band for GFAP. In both CVPC aggregates not treated with RA
no bands were visible. This concludes that upon differentiation CVPC possessed no
TH- or GFAP- expressing cells, while treated with RA a different subset of genes was
activated. Similar results were seen in SSC clone He2P11K13/5 cells. Undifferentiated
He2P11K13/5 cells showed no expression of TH, but a low amount of GFAP. Upon
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Figure 4.30: Expression profiles of ESC AB2.2, CVPCs and SSCs. Undifferentiated
cells, untreated aggregates and RA-treated aggregates (d15) were analyzed by RT-PCR
for the expression of TH and GFAP as indicated.
differentiation expression of neuronal markers was absolutely absent. Aggregates
treated with retinoic acid behaved like H3 aggregates and expressed GFAP. The SSC
clone Hi2P11K15/6 was the only cell clone that behaved quite different. This clone,
isolated from the murine brain, showed upon differentiation in aggregates expression
of both neuronal markers. The expression of these two markers was increased by
exposure to retinoic acid. Interestingly, CVPC clones and SSC clone He2P11K13/5
showed either TH or GFAP expression, but both markers were never expressed at the
same time, whereas we observed expression of both markers in Hi2P11K15/6. CVPC
clone H3 and SSC clone He2P11K13/5 cells showed the same expression profile as
seen in ESC AB2.2.
4.2 INFLUENCE OF MAPK CASCADE PATHWAY ON CARDIOMYOGENESIS
The MAPK cascade is an important pathway for cell proliferation and differentiation
(Seger and Krebs, 1995). Especially during differentiation its activity is critical for cell
fate decisions of embryonic stem cells (Aouadi et al., 2006). Aouadi and colleagues
demonstrated in their differentiation studies that MAPK activity is necessary to
induce cardiomyogenesis.
To study the involvement of mitogen-activated protein kinases (MAPKs) in car-
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diomyogenesis of CVPCs, aggregated CVPC clone A5 cells were treated with MEK1
inhibitor PD98059. To investigate the influence of PD98059 on the formation of
cardiomyocytes the percentage of beating aggregates was determined daily over a
period of twenty days. CVPC clone A5 cells were cultured as hanging drops for five
days followed by rinsing them onto gelled culture plates. The inhibitor (10µM) was
added for different time intervals, from days 0-5, 5-7, 7-10 and 10-13. The experiment
indicated an influence of PD98059 at very early developmental stages (0-5), whereas
later no effect was visible. A decrease in the number of beating cardiomyocytes and
a delayed onset for two days was observed from days 0-5 (Gottschamel, 2010).
Though the MEK1 inhibitor was shown to negatively influence cardiomyogenesis, it
had no effect on morphology of aggregates when added on days 0-5 (Figure 4.31).
Figure 4.31: Morphology of untreated (A) and treated (B) aggregates. PD98059 (5µM)
was added to CVPC clone A5 aggregates on days 0-5.Images were made on day 7 of
cultivation (bar=500µm).
These results were verified by repeating the previous experiment using half of the
PD98059 concentration (5µM). Although we even reduced the concentration the same
effect was visible. Only by adding the MEK1 inhibitor on days 0-5 we obtained a
reduction in beating capacity (Figure 4.32).
Here we could prove the influence of PD98059 (5µM) on cardiomyogenesis only in
early stages of development. Even by increasing the concentration of the inhibitor to
20µM did not change the fact that PD98059 is only effective in early developmental
stages (Figure 4.33).
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Figure 4.32: Influence of 5µM PD98059 on beating aggregates. PD98059 was added on
days 0-5. CVPC clone A5 aggregates were made and percentage of beating aggregates
was determined over a period of 21 days. Data are means of 4 culture plates (10 counts
per plate) each treated and untreated.
Figure 4.33: Influence of 20µM PD98059 on beating aggregates. CPVC clone A5
aggregates were cultured as hanging drops for five days. They were rinsed onto gelatin-
coated culture plates. The MEK1 inhibitor was added from days 0-5, 7-10, 10-13.
Percentage of beating aggregates was determined every day for a period of 24 days. Data
from days 5-7 are not included in the figure, because aggregates were smaller than normal
and therefore beating capacity was already reduced independently of the presence of
inhibitor. Data are means of 4 culture plates (10 counts per plate) each treated and
untreated.
Next we investigated the influence of PD98059 on cardiomyogenesis by adding the
inhibitor for longer time periods. Aggregated CVPC clone A5 cells were treated with
the MEK1 inhibitor (5µM) on days 5-13 and 0-13. Though the inhibitor was given
for the long period of nine days (days 5-13) no reduction in the occurrence of beating
aggregates was seen. While adding PD98059 from days 0-13 again a strong inhibitory
effect was visible (Figure 4.34).
As assumed cardiomyogenesis was not influenced by adding the MEK1 inhibitor
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Figure 4.34: Effect of 5µM PD98059 when added for longer time periods. CVPC clone
A5 aggregates were treated with PD98059 for days 5-13 and 0-13.
on days 5-13. Now we can really exclude a negative effect of PD98059 in later
developmental stages. Even when the inhibitor is present over a longer period no
effect on cardiomyogenesis was determined. During the investigations we recognized
not only an influence on beating cardiomyocytes, also contracting smooth muscle
cells seemed to be influenced by PD98059 (Figure 4.35). By adding the inhibitor
in early stages of development a significant reduction in contracting smooth muscle
cells was determined, while the presence of the inhibitor on days 5-13 showed a slight
enhancement of contractions. This indicated a time dependent action of the MEK1
inhibitor on smooth muscle cell formations.
Figure 4.35: Effect of PD98059 on contracting smooth muscle cells. The inhibitor was
added from days 5-13 and 0-13.
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4.2.1 Effect of MEK 1 Inhibition on Nkx2.5 gene Expression
Because we could observe an influence of PD98059 on cardiomyogenesis, we investi-
gated also the effect of the inhibitor on Nkx2.5 gene expression. The Nkx2.5 gene
is a cardiac marker involved in cardiomyogenesis. To determine gene expression
we made use of the A5-CSX reporter cell line by detecting the EGFP signal which
correlates with the Nkx2.5 expression by FACS analysis. Due to the fact that the
MEK1 inhibitor is only effective by adding it in early stages of aggregate development
we added PD98059 on days 0-7. Before the formation of hanging drops the inhibitor
was added in a concentration of 5µM. After five days of cultivation of CVPC clone
A5-CSX aggregates as hanging drops we rinsed them onto gelatin-coated 10cm cul-
ture plates. FACS analysis was performed on days 7, 13 and 20 and percentage of
EGFP positive cells was determined (Figure 4.36). On day 7 the Nkx2.5 expression
was significantly reduced compared to control, while FACS analysis on days 13 and
20 showed no change in expression profile. The presence of the inhibitor at early
developmental stages not only decreased the occurrence of beating cardiomyocytes,
also a strong decrease in Nkx2.5 gene expression was obtained.
Figure 4.36: Effect of PD98059 on Nkx2.5 gene expression. FACS analysis of undif-
ferentiated and differentiated CSX A5 cells on day 7, 13 and 20. Data are means of
duplicates. (Stand.Dev. .. standard deviation)
4.3 INFLUENCE OF SPARC, ANIT-SPARC, BMP2/4 AND ANTI-BMP2/4 ON
NKX2.5 EXPRESSION
Here, we concentrated on the investigation of the Nkx2.5 gene expression in CVPCs.
The Nkx2.5 gene becomes important during heart development and its activation
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depicts commitment of cells to the cardiac lineage (Lyons et al., 1995). Therefore,
Nkx2.5 is an adequate marker for the identification of cardiac progenitor cells.
To study Nkx2.5 gene expression we made use of the EGFP-Nkx2.5 reporter cell
line, called A5-CSX (Gottschamel, 2010). This cell line was exclusively used in the
following experiments where we investigated the Nkx2.5 gene expression during the
course of differentiation by FACS analysis. Additionally, we studied the influence
of cardiomyocyte-stimulating factors, like recombinant SPARC and BMP2/4 in
undifferentiated and differentiated A5-CSX cells.
4.3.1 Nkx2.5 Gene Expression during Emrbyoid Body-like Aggregate Development
Here we concentrated on the investigation of the Nkx2.5 gene expression in CVPCs.
The A5-CSX reporter cell line was used to measure Nkx2.5 gene expression during the
course of differentiation by FACS analysis. Therefore A5-CSX cells were cultured as
hanging drops for five days followed by rinsing them onto gelled 10cm culture plates.
For control A5 cells not carrying the EGFP marker gene were treated and analyzed
the same way. Aggregates were measured on days 5, 7, 10 and 13 by FACSCalibur.
Undifferentiated (day 0) CVPC clone A5-CSX showed a strong expression of Nkx2.5,
while upon initiation of differentiation an almost linear decrease in expression was
observed (Figure 4.37).
These results are contrary to previous results from RT-PCR experiments that revealed
an upregulation of Nkx2.5 mRNA upon differentiation (Hoebaus, 2009). A possible
explanation could lie in the complex transcription and translation machinery. While
RT-PCR is based on mRNA and reflect the process of gene transcription, the results
determined by using A5-CSX reporter cell line and FACS analysis also include
the process of translation. We assume that undifferentiated A5-CSX cells produce
adequate amounts of Nkx2.5 mRNA followed by fast translation into protein, which
would explain the high percentage of cells expressing EGFP and the accompanied
loss of mRNA. During differentiation less Nkx2.5 protein is required, therefore we
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Figure 4.37: The Nkx2.5 expression during aggregate development. Undifferentiated
and differentiated A5-CSX2 cells were analyzed by FACS. Therefore aggregates were
made and Nkx2.5 expression was determined at different time points (days 0, 5, 7, 13).
Almost 90% of the measured undifferentiated cell population expressed EGFP, while cell
aggregates on day 13 possessed only 14% EGFP(+) cells. Data are means of duplicates.
can see a decrease in EGFP (+) cells and an increase on mRNA-level. It might be
the explanation why we obtained different results.
4.3.2 Effect of BMP2/4 on Nkx2.5 gene Expression
Recent studies on ALK3 receptor expression by RT-PCR analysis revealed that
CVPCs use BMP signaling and presumably plays a critical role during differentiation
and cardiomyogenesis (Hoebaus, 2009). Other studies suggested also the need of
BMP signaling during cardiac development (Zhang and Bradley, 1996). To get deeper
insights of the importance of BMP signaling we tested CVPCs for the expression of
BMP2/4. RT-PCR analysis was performed with primer pairs for BMP2/4 (Figure
4.38). All tested CVPC clones expressed high levels of BMP2/4 in the undifferentiated
state. Expression rate of CVPC clones were higher compared to ESC AB2.2 cells.
Figure 4.38: RT-PCR analysis of undifferentiated CVPC clones A5, G3 and H3 and
ESC AB2.2 cells with primer pairs for BMP2/4.
Previous experiments with CVPCs revealed a positive effect of BMP2/4 on cardiomyo-
genesis by increasing the number of beating cardiomyocytes, while anti-BMP2/4
4 RESULTS 57
antibodies slightly inhibited cardiomyogenesis (Hoebaus, 2009). Therefore we next
focused on the effect of BMP2/4 on Nkx2.5 gene expression.
To investigate the influence of BMP2/4 and anti-BMP2/4 on Nkx2.5 expression un-
differentiated A5 and A5-CSX cells were trypsinised and 3 x 105 cells were transferred
onto gelatin-coated 24-well culture plates. After 24 hours BMP2/4 (0.1 µg/ml) and
anti- BMP2/4 (1.5 µg/ml) were added for 3 hours, 24 hours and 3 days and the
quantitative differences in the EGFP expression was measured by FACS analysis.
Because cells were not longer cultured on feeder layers, but as a monolayer cultures we
could observe differences in the Nkx2.5 gene expression compared to control cultures
(3h, 24h, 3d) (Figure 4.39, A). The observed reduction on Nkx2.5 gene expression
might be due to the fact that cells were grown as monolayer culture in the absence
of LIF-producing feeder cells for different time periods. Without LIF, cells start to
differentiate resulting in changed Nkx2.5 expression profile. To compare the effect of
BMP2/4 and anti- BMP2/4 it was necessary to created a base line by dividing FACS
values through the mean value of CSX control. Neither treatment with BMP2/4 nor
with anti-BMP2/4 resulted in a significant difference in Nkx2.5 gene expression in
undifferentiated CVPC clone A5-CSX cells. Even the presence of these factors for
three days showed no effect (Figure 4.39, B).
Next we analyzed the influence of these factors in differentiated CVPCs. Therefore
A5 and A5-CSX cells were cultured as hanging drops and were rinsed on day five onto
gelatin-coated 10cm culture plates. Because Nkx2.5 expression was lowest on day
13 of aggregate cultivation BMP2/4 (0.1µg/ml) and anti-BMP2/4 (1.5µg/ml) were
added at this time point for 3 and 24 hours and the Nkx2.5 expression was determined
by FACS analysis. Differentiated cells treated with BMP2/4 and anti-BMP2/4 for
three and 24 hours showed an effect on Nkx2.5 gene expression. Addition of BMP2/4
for 3 hours resulted in no significant change in expression, but presence of BMP2/4
for 24 hours resulted in a downregulation in expression. Unexpectedly presence of
anti-BMP2/4 showed an enhancement in Nkx2.5 gene expression during the first
3 hours, but after 24 hours a significant decrease in Nkx2.5 gene expression was
detectable (Figure 4.39, C).
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Figure 4.39: Influence of BMP2/4 on Nkx2.5 gene expression. A: Differences in Nkx2.5
gene expression in CSX control cultures. While cells cultured as monolayer for three hours
showed 90% EGFP(+) cells, a slight reduction in Nkx2.5 gene expression was observed
in monolayers deprived of LIF for 24 hours and three days ( 81%). B: Undifferentiated
A5-CSX cells were treated with BMP2/4 and anti-BMP2/4, respectively for indicated
time intervals. C: A5-CSX cells were cultured as hanging drops for five days and were
rinsed onto gelled culture plates. Addition of BMP2/4 (0.1µg/ml) and anti-BMP2/4
(1.5µg/ml) on day 13 of aggregate formation for the indicated time periods. FACS values
were divided by mean value of CSX control to obtain a constant basis line to compare the
effect on Nkx2.5 gene expression. Data are means of duplicates. For standard deviation
see Appendix.
4.3.3 Effect of SPARC on Nkx2.5 gene Expression
Here we determined the influence of SPARC (3 µg/ml) and anti-SPARC (1:100) on
the Nkx2.5 gene expression of undifferentiated and differentiated CVPCs with FACS
analysis. Thereby the same procedure was used as previously mentioned and the
quantitative difference in EGFP expression of A5-CSX cells was measured again.
Analysis of CVPCs in an undifferentiated state revealed similar results as seen by
addition of BMP2/4. Neither recombinant SPARC nor anti-SPARC had an influ-
ence on Nkx2.5 gene expression of undifferentiated CVPC clone A5-CSX (Figure 4.40).
Previous transfection experiments confirmed our findings. Undifferentiated CVPCs
exposed to SPARC for 48 hours lead to no significant differences in Nkx2.5 gene
expression (Hoebaus, 2009). This observations let us assume that the Nkx2.5 gene
expression in undifferentiated CVPCs is too high to be affected by SPARC or anti-
SPARC. It also might be possible that SPARC and anti-SPARC have no influence on
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Figure 4.40: The Nkx2.5 gene expression in undifferentiated CVPC clone A5-CSX in
presence of SPARC and anti-SPARC. Addition of SPARC (3µg/ml) and anti-SPARC
(1:100) for the indicated time periods. Data are means of duplicates.
gene expression at this time point. But it seemed that CVPCs gain their accessibility
toward SPARC during differentiation (Gottschamel, 2010). Here, CVPC aggregates
exposed to SPARC from days 5-7 showed an increase in cardiomyogenesis, while
anti-SPARC negatively influenced cardiomyogenesis.
Because CVPCs are susceptible toward SPARC during aggregate development, we
next studied the effect of SPARC and anti-SPARC in CVPC aggregates on day 13
of cultivation. Differentiated cells exposed to SPARC for 3 hours showed an en-
hancement of Nkx2.5 gene expression. But this activation of gene expression elapsed
rapidly and after 24 hours a decreased expression was left. This initial enhancement
comprised 0.7-fold more EGFP(+) cells with SPARC as without SPARC (Figure
4.41, A).
Similar results were achieved by using the transfection protocol adapted for CVPCs
and performing luciferase assays (Figure 4.41, B). Again hanging drops were made
with CVPC clone A5. On day 5 the formed aggregates were rinsed onto gelled 10cm
culture dishes. Aggregates were cultured till day 9 and were next trypsinized and
disseminated onto a gelled 48-well-plate with a concentration of 6 x 104 cells/ 500µl.
After 24 hours cells were transfected with a Renilla plasmid used as internal control
encoding a Renilla luciferase reporter gene that is constantly expressed in each cell.
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Renilla (reniformis) luciferase originates from the sea pansy and is used to determine
transfection efficiency. Additionally cells were transfected with a control pGL3 -Basic
vector encoding a luciferase gene without a promoter region. To make visible the
effect of SPARC and neutralizing anti-SPARC on the Nkx2.5 gene expression, cells
were further transfected with a NKE24 plasmid. The NKE24 plasmid is identical to
pGL3b plasmid, but contains an insert of the Nkx2.5 promoter region in front of the
luciferase reporter gene. Lipofectamine 2000 reaction was stopped after 3 hours. 48
hours after transiente transfection SPARC (3µg/ml) and anti-SPARC (1:100) were
added for 4 and 24 hours. Luciferase assays were made and Renilla and Firefly values
were measured with a luminometer to determine the expression level of the reporter
gene.
Figure 4.41: The Nkx2.5 gene expression in differentiated CVPC clone A5. A: FACS
analysis. A5-CSX cells were cultured as hanging drops for five days and were rinsed
onto gelled culture plates. Addition of SPARC (3µg/ml) and anti-SPARC (1:100) on
day 13 of aggregate formation for the indicated time periods. FACS values were divided
by mean value of CSX control to obtain a constant basis line that make it able to
compare the effect of SPARC and anti-SPARC on Nkx2.5 gene expression. Data are
means of duplicates. For standard deviation see Appendix. B: Luciferase gene expression.
CVPC clone A5 aggregates were trypsinized on day 9 of cultivation and were seeded (6
x 104 cells/ 500µl) onto gelled 48-well-plates. Transient transfection was performed with
Lipofectamine 2000. Plasmid DNA (1000ng) to Renilla DNA ratio was 100:1. Values
are mean of duplicates and are indicated as firefly/renilla ratios.
Data obtained from luciferase experiments are similar to FACS results. Addition of
SPARC for 4 hours resulted in an increase of luciferase activity and therefore in an
enhancement of Nkx2.5 expression. While FACS analysis showed that anti-SPARC
had no effect on Nkx2.5 expression not before an incubation time of 24 hours is
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reached, luciferase assay data revealed a significant inhibition of expression even
after 4 hours. These differences could be explained by the fact that in both cases a
different sample of anti-SPARC was used.
4.3.4 Effect of SPARC on CVPC gene Expression
It was already shown that undifferentiated CVPC clone A5 cells express to a very low
extent GATA4 on mRNA level. This expression of the myocardial marker indicated
a commitment of CVPCs to the cardiac lineage. Upon differentiation of CVPC
clone A5 aggregates the expression profile gets altered. Aggregates showed a strong
enhancement in GATA4 expression compared to undifferentiated A5 cells (Hoebaus,
2009).
Next we determined the effect of SPARC on the expression of defined genes in undif-
ferentiated CVPC clone A5 cells. SPARC was added for three hours and RT-PCR
analysis with primer pairs for BMP2, GATA4, TBX5 and ILK1 was performed.
SPARC was able to enhance expression of the genes GATA4, TBX5 and ILK1,
whereas gene expression of BMP2 was slightly decreased (Figure 4.42).
Figure 4.42: Influence of SPARC on genes BMP2, GATA4, TBX5 and ILK1 in
undifferentiated CVPC clone A5 cells. RT-PCR analysis with indicated primer pairs
were performed on untreated A5 cells and cells treated with SPARC for three hours.

5 DISCUSSION
5.1 DIFFERENTIATION POTENTIAL OF CVPCs
5.1.1 Morphological Differences upon Differentiation
In the presence of LIF-producing feeder cells CVPCs maintain their self-renewing
potential. Under LIF deprivation cells start to differentiate into three types residing in
the heart. Thereby their change their morphology and form cardiomyocytes, smooth
muscle cells and endothelial cells (Hoebaus, 2009). For differentiation studies we
used the well known embryoid body system by generating embryoid body-like CVPC
aggregates and determined morphological changes compared to embryoid bodies with
ESC AB2.2 and between CVPC clones itself. As figure 4.3 shows we can observe
a difference in aggregate size between ESC AB2.2 and CVPC aggregates. While
AB2.2 embryoid bodies tended to form horse-shoe-like shaped dense areas in the
center of the aggregates, CVPC embryoid body-like aggregates possessed never such
defined structure. CVPC aggregate morphology seems to be more chaotic. We can
distinguish AB2.2 aggregates from CVPC aggregates by investigating the location
of the dense core, which seems to be in CVPC aggregates in the middle of the
aggregates, while in embryoid bodies it is not centered. Between CVPC clones itself
no morphological differences were observed, except that CVPC clone H3 aggregates
seemed often smaller compared to A5 aggregates. During aggregate development
cells start to spread from the core to the periphery thereby differentiating to diverse
but limited cell types. The compact core consists of round shaped cells which are
surrounded by less dense differentiated cells with elongated, round or angular shaped
structure (Figure 4.4).
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5.1.2 CVPCs are Restricted to the Cardiac Lineage
FACS analysis and confocal scanning immunofluorescence microscopy proved a limited
differentiation potential of CVPCs. With both methods we analyzed the potential of
CVPC aggregates to differentiate spontaneously into distinct cell types of the three
germ layers ectoderm, endoderm and mesoderm. Therefore, we stained aggregates
with antibodies against FOXA2, vWF, GFAP, beta3-tubulin, cTnT and SMA on day
13 of cultivation.
Confocal scanning immunofluorescence microscopy revealed a very limited differentia-
tion potential of CVPCs. Figure 4.5 shows an absence of cells expressing beta3-tubulin
and GFAP. These two markers are specific for the ectodermal layer, especially for the
neuronal lineage. The absence of any positive signal indicates that CVPC lack the
potential for neuronal differentiation at least on day 13 of cultivation. Even in later
days of cultivation (d20) no beta3-tubulin expressing cells could be observed in CVPC
clone A5 aggregates (not shown). Surprisingly, quantitative FACS analysis revealed
data contrary to immunofluorescence microscopy. Here, GFAP-expressing cells were
quite common among the CVPC population, while immunofluorescence microscopy
depicted an absence of these cells. Beta3-tubulin positive cells were absent in A5
and very low in H3 aggregates. This extremely low incidence in H3 aggregates can
be declined as background signals during FACS measurement. Immunofluorescence
microscopy revealed an absence of FOXA2-expressing cells in CVPC aggregates, but
FACS analysis showed an occurrence rate of 1-2 % in H3 and A5 cell populations.
Cells expressing vWF could only be observed during immunofluorescence microscopy
by electronic amplification of the output signal. This output signal seemed to be
too weak to be recognized only by the naked eye. Indeed, we could recognize a
wide distribution of vWF-expressing cells in CVPC aggregates, but data received
from FACS analysis revealed an occurrence rate of nearly 100%, which seemed to
be too high. Importantly, we could observe cTnT and SMA expressing cells during
immunofluorescence microscopy and even FACS analysis proved the presence of these
cell types.
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Unfortunately data from immunofluorescence staining and FACS analysis were very
contradictorily. We can exclude that the reason for this contradiction are due to the
antibodies, because in both experiments the same primary and secondary antibodies
were used. Maybe, FACS analysis was more sensitive to fluorescence signals and
therefore measured even background signals. This would explain the high occurrence
rates and the presence of signals, which were more infrequent or even absent during
immunofluorescence microscopy. Another possibility for the divergence could be the
different methods used to prepare aggregates for staining and the staining proce-
dure itself. For FACS analysis cells were exposed to harsh mechanical stress during
separation of cells and during staining procedure. While for microscope analysis
aggregates itself were stained and therefore were more gently treated. One important
fact to mention is the method of detaching cells from the layer by trypsin. Trypsin
may have an effect on cell morphology and expression profile. So we decided to
trust more datas received from immunofluorescence microscope analysis than FACS
data. We more or less concluded that the FACS analysis is not well suited as the
method for analyzing the distribution of cell types and the quantitative determination.
These results indicated an absence of the ability of CVPCs to spontaneously differ-
entiate to cells of the ectodermal lineage. We could already observe the absence of
such cell types under the light microscope. We could also show that CVPCs are
restricted in their endodermal differentiation potential. While we could observe vWF-
expressing cells, we never observed FOXA2 positive cells. Investigations under the
light microscope also revealed the presence of rhythmically beating cardiomyocytes,
slowly contracting smooth muscle cells and endothelial-like cells. Stainings with
anti-cardiac troponin T, anti- smooth muscle actin and anti-vWF antibodies showed
the presence of cells expressing these markers. Other groups already succeeded in
the isolation of precursor cells expressing cardiac markers and thereby demonstrating
the commitment to the cardiac lineage (Tallini et al., 2009; Pfister et al., 2005).
By comparing cardiac cells derived from AB2.2 and CVPC clones A5 and H3,
respectively we could recognize that A5 aggregates possessed more cTnT- and SMA-
expressing cells compared to AB2.2, while H3 aggregates revealed a lower frequency
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(Figure 4.8). These findings were confirmed by data received during the study of
beating capacity of A5 and H3 aggregates under the light microscope. There, a
different frequency of beating cardiomyocytes could be observed among CVPC clones.
Although immnofluorescence microscopy proved the presence of cTnT-expressing cells
in both CVPC clones, H3 seemed to have a reduced cardiomyogenese compared to
A5 aggregates.
5.1.3 CVPCs can be Induced to Neuronal Differentiation by Retinoic Acid
Here we wanted to test if CVPCs are able to form neuron and glia cells by induction by
retinoic acid. Addition of high concentrations of retinoic acid to aggregates resulted
in the formation of neuron-like cells (Figure 4.26). Investigation of CVPC aggregates
under the light microscope revealed the presence of cells with typical structures seen
in neuronal cells of the brain. Because of the similar phenotypical appearance we
concluded that the observed cells are neuron-like cells. Neuron-like cells possessed a
cell body with neurites arising from the cell body and reaching far into periphery.
Such cells were mainly seen in the periphery of aggregates and never in the dense
center. Unfortunately, we were not able to absolutely define these cells as neuron-like
cells, because of the absence of any positive signal for antibodies specific for neuronal
differentiation. Immunofluorescence staining with anti-beta3-tubulin and anti-GFAP
antibodies was negative for cells expressing these neuronal markers (Figure 4.25). But
RT-PCR analysis bared the expression of neuronal markers like tyrosine hydroxylase
and glial fibrillary protein upon exposure of aggregates to retinoic acid (Figure 4.30).
Interestingly, we recognized a diverse expression profile among A5 and H3 embryoid
body-like aggregates. While ESC AB2.2 embryoid bodies showed a slow increase of
neuron-like cells during first days of aggregate development, neuron-like cells occur-
rence proceeded faster in CVPC aggregates. Compared to embryoid bodies, CVPC
aggregates were not able to maintain the continuous presence of neuron-like cells,
because in later days the occurrence rate fell. In contrast to AB2.2 embryoid bodies,
CVPC aggregates hardly never reached hundred percent (Figure 4.26). Differences in
the formation of neuron-like cells could also be observed among CVPC aggregates.
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A5 cells seemed to have a more reduced potential to keep their neuron-like cells alive
compared to H3. Although in A5 clone neuron-like cells were observed already on day
8 (compared to H3 one day after), they decreased more rapidly compared to CVPC
clones H3 (Figure 4.26). Without treatment with retinoic acid we never observed
the formation of neuron-like cells in both CVPC clones (Figure 4.28). In conclusion,
data support the notion that CVPCs can not give rise to ectodermal somatic cells
without induction.
5.1.4 Retinoic Acid is Able to Inhibit Cardiomyogenesis in CVPC Aggregates
CVPC aggregates treated with retinoic acid were much smaller in size compared
to untreated aggregates (Figure 4.17). It seemed that retinoic acid prevents differ-
entiation and cell spreading into the periphery. Cardiac differentiation was clearly
inhibited as observed by immunofluorescence staining and determining the percentage
of beating aggregates. Cells expressing cTnT were absolutely absent in aggregates
treated with retinoic acid (Figure 4.20, A). This observation was proved by the strong
reduction of beating cardiomyocyte formation resulting in fewer beating aggregates
(Figure 4.18). With a CVPC cell line carrying an EGFP reporter gene under the
control of the Nkx2.5 promoter and FACS analyzing we observed a reduction in
Nkx2.5 gene expression upon exposure to retinoic acid. Either adding retinoic acid
to undifferentiated CVPCs or to differentiated aggregates resulted in a decrease in
expression (Figure 4.21; Figure 4.22). This explains the dual potential of retinoic
acid to promote neuronal differentiation by preventing cardiomyogenesis at the same
time.
5.2 REGULATION OF CARDIOMYOGENESIS
Cardiomyogenesis is a complex network of regulated gene expression and signal
transduction. Extracellular signals are involved in the activation of transcription fac-
tors that enter the nucleus and activate a subset of genes involved in cardiomyogenesis.
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5.2.1 Inhibition of MAPK Cascade Resulted in a Reduction of Cardiomyogenesis
The mitogen-activated protein kinase (MAPK) pathway is a signaling cascade that
convert extracellular signals into intracellular activation of distinct transcription
factors involved in cell proliferation and differentiation. Studies have revealed the
influence of MAPK pathway in cardiomyocyte differentiation in P19 cells (Eriksson
and Leppä, 2002). Here, similar results on cardiomyogenesis were achieved by adding
PD98059, the MEK1 inhibitor to CVPC aggregates. While MEK1 inhibition showed
no effect on aggregate morphology, we observed a negative effect on cardiomyogenesis.
Addition of the inhibitor resulted in a reduced beating capacity. Low concentrations of
the inhibitor already decreased the occurrence rate of beating cardiomyocytes in first
days of aggregate development (Figure 4.32). Even by increasing the concentration
of the inhibitor to 20µM did not change the fact that PD98059 is only effective
in early developmental stages (Figure 4.33). In general, the onset of contraction
was delayed and 50-60 % less beating aggregates could be observed. Inhibition at
later stages of aggregate development did not affect cardiomyogenesis. Even adding
the inhibitor for longer time periods resulted in no reduction of beating capacity.
Only the presence of the inhibitor at the time point of aggregation (d0) resulted
in a delayed onset of cardiomyogenesis (Figure 4.34). So we can really exclude an
influence on cardiomyogenesis in later stages of development, whether increasing the
concentration nor adding the inhibitor for longer time intervals. We further could
recognize a time dependent action of the MEK1 inhibitor on smooth muscle cell
formation. While the presence of PD98059 from day 0 on resulted in a prevention of
contracting smooth muscles, the addition of the inhibitor from day 5 on enhanced
SMC formation (Figure 4.35).
We could confirm a prevention of cardiomyogenesis also by observation of Nkx2.5
gene expression during MEK1 inhibition. We recognized a significant reduction of
Nkx2.5 expression in first days of aggregate development(Figure 4.36).
These facts indicated that the MAPK cascade plays an important role in cardiomyoge-
nesis by influencing the onset as well as the occurrence rate of beating cardiomyocytes
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and contracting smooth muscle cells. Thereby the MAPK signal transduction pathway
positively influences the differentiation of CVPCs to cardiomyocytes and smooth
muscle cells during early developmental stages and simultaneously inhibits contrac-
tions of smooth muscle cells in later phases of development.
5.2.2 Influence of SPARC, anti-SPARC, BMP2/4 and anti-BMP2/4 on Nkx2.5
Expression
The Nkx2.5 gene is known as a cardiac marker with important functions during heart
development. First commitment of cells to the cardiac lineage is indicated by the
expression of Nkx2.5 (Jamali et al., 2001). Progenitor cells residing in the heart are
shown to express Nkx2.5 (Saga et al., 2000) and this expression seems to be essential
for survival and proliferation of precursor cells (Lyons et al., 1995). Undifferentiated
CVPCs are characterized by high expression levels of Nkx2.5. Upon differentiation it
came to an almost linear decrease in expression (Figure 4.37). These findings indicate
CVPCs to be cardiac progenitor cells that are already committed to the cardiac
lineage due to their expression of Nkx2.5 in their undifferentiated state.
Bone morphogenetic protein (BMP) belongs to the subfamily of the TGF-beta su-
perfamily and plays important roles in proliferation, differentiation and migration.
BMPs are expressed during heart development and the interplay of BMP repression
and stimulation is critical for cardiomyocyte differentiation (Yuasa and Fukuda, 2008).
BMP2 has the potential to specify cells to the cardiac lineage (Lough et al., 1996)
and is critical for the specification of the cardiogenic mesoderm (Schlange et al.,
2000). The BMP-signaling pathway activates Smad1 by phosphorylation and this
results further in the activation of cardiac genes (Callis et al., 2005). Inhibition of
BMP signaling resulted in a prevention of cardiomyocyte differentiation in Flk1+
progenitor cells (Yamashita et al., 2005). Also our isolated CVPC cell line revealed
the importance of BMP2. Undifferentiated CVPCs express high amounts of BMP2
what was seen during RT-PCR analysis. Previous experiments revealed the positive
influence of BMP2 on cardiomyogenesis in CVPCs (Hoebaus, 2009). Here, we were
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not able to show a positive effect of BMP2 signaling on the Nkx2.5 gene expression,
although we assumed an upregulation in expression due to findings that revealed
BMP2 as a positive regulator for cardiomyogenesis. Neither in undifferentiated nor
in differentiated CVPC clone A5 aggregates we could see the presumed positive
effect. Instead, we had to recognize that BMP2 had no effect in undifferentiated
cells at all, but a negative effect in differentiated cells exposed to BMP2 for 24 hours.
Unexpectedly, presence of anti-BMP2/4 during later stages of differentiation showed
an enhancement in Nkx2.5 gene expression after 3 hours, but decreased rapidly after
24 hours (Figure 4.39).
Previous experiments revealed already the positive effect of SPARC on cardiomyoge-
nesis (Gottschamel, 2010). Nkx2.5 gene expression in undifferentiated CVPCs was
not influenced by the presence of SPARC or anti-SPARC. However, experiments on
differentiated CVPCs revealed an enhancement of Nkx2.5 gene expression after 3
hours, while anti-SPARC showed a decrease in expression after 24 hours (Figure
4.41). The positive influence of SPARC on cardiomyocyte differentiation revealed
also an upregulation of cardiac markers like Nkx2.5, troponin, BMP-2 and MHCalpha
(Hrabchak et al., 2008). Undifferentiated CVPCs exposed to SPARC revealed altered
gene expression profiles concerning BMP2, GATA4, TBX5 and ILK1. While it
seemed that BMP2 expression was decreased, GATA4, TBX5 and ILK1 expression
was enhanced upon SPARC exposure. The T-box gene tbx5 is like BMP2 expressed
during heart development. Expression of tbx5 proceeds early in the developing heart
together with Nkx2.5 and GATA4 expression (Liberatore et al., 2000). The GATA4
gene is expressed in the primary and secondary heart field and presumably plays
an important role during heart development (Waldo et al., 2001). The Nkx2.5 gene
is known to have binding sites for GATA4 and elimination of this binding sites
results in a loss of early cardiac gene activation. This hints at a GATA-dependent
controlling of Nkx2.5 gene expression (Searcy et al., 1998). Interestingly, treatment of
undifferentiated CVPCs with recombinant SPARC resulted in an increase of GATA4
gene expression.
In conclusion, CVPCs expressed cardiac transcription factors like Nkx2.5 and BMP2
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in their undifferentiated state and possessed a decreased Nkx2.5 gene expression upon
differentiation. These results defined CVPCs to be presumably cardiac progenitor
cells. Further findings demonstrated that recombinant SPARC is able to enhance
expression of diverse cardiac genes, which in turn indicated SPARC as a positive
regulator of cardiomyogenesis.
5.3 SUMMARY
So far we know that CVPCs can be kept in an undifferentiated state by cultiva-
tion on LIF-producing feeder cells thereby activating STAT3 signaling pathway and
preventing differentiation (Hoebaus, 2009). From RT-PCR analysis we know that
CVPCs have both embryonic and cardiac character by expressing stemness tran-
scription factors like Oct4, Sox 2 and Nanog as well as myocardial transcription
factors such as Brachyury, Nkx2.5, GATA4 and Isl1 (Hoebaus, 2009). As proved by
immunofluorescence microscopy we conclude that CVPCs are able to differentiate to
cell types residing in the heart exclusively. They spontaneously differentiate to cardiac
troponin T-expressing cardiomyocytes, contracting smooth muscle cells expressing
SMA and vWF-expressing endothelial cells. Presumptive ectodermal cells could only
be observed by induction with high concentrations of retinoic acid. This resulted in
the formation of neuron-like cells, which however, never expressed neuron specific
genes except on mRNA level.
5.4 DIFFERENTIATION POTENTIAL OF SSCs
5.4.1 Morphological Differences Upon Differentiation
As seen in CVPCs, SSCs cultured on LIF-producing feeder cells maintain their undif-
ferentiated state and start to differentiate under LIF deprivation. Upon differentiation
SSCs change their cell structure and form distinct cell types. While He2P11K13/5
cells were isolated from the murine heart, Hi2P11K15/6 cells were isolated from the
brain. Because of their diverse origin we assumed that cells could differentiate to
different cell types. For Hi2P11K15/6 we believed a restriction to the neuronal lineage
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based on their isolation from the murine brain and He2P11K13/5 were assumed to
be committed to the cardiac lineage as seen in CVPC clones.
Embryoid body-like aggregates of Hi2P11K15/6 and He2P11K13/5 were the largest
one compared to AB2.2 embryoid bodies and CVPC aggregates (Figure 4.11).
Hi2P11K15/6 aggregates often seemed to have a very diffuse structure where the
dense core was often not centered. He2P11K13/5 aggregates often possessed a stellar
shaped core and a defined edge in the outer peripheral area. But also aggregate
structures as seen in Hi2P11K15/6 could be observed in He2P11K13/5. An expert
eye could distinguish these two SSC aggregates by their morphological differences.
Upon differentiation cells spread from the dense core to the periphery and start
to differentiate to several cell types. As seen in CVPC aggregates the compact
core consists of round shaped cells which is passed to less dense elongated, round
or angular shaped cells. SSC aggregates can be distinguished easily from CVPC
aggregates in their morphological differences. Another difference could be observed
by investigating their differentiation potential. While CVPC aggregates seemed to
be restricted to the cardiac lineage, SSC aggregates seemed to have a more extended
differentiation potential. In both SSC clones we could observe cells with structures
identical to neuronal cells. Although such cells could only be observed infrequently,
they possessed the potential for neuronal differentiation (Figure 4.12).
5.4.2 SSC Clone Hi2P11K15/6 is More or Less Restricted to The Neuronal Lineage
Differentiation studies revealed the potential of Hi2P11K15/6 to spontaneously dif-
ferentiate to neuron-like cells. Because of the isolation from the murine brain we
were not surprised by the appearance of neuron-like cells during investigations under
the light microscope. Neuron-like cells featured a cell body and dendrites emerging
from the body. Further we recognized expression of the neuronal markers GFAP
and TH in aggregates, while no expression was seen in CVPC aggregates (Figure
4.30). The occurrence rate of neuron-like cells was slightly lower than in AB2.2
embryoid bodies and first appearance of these cells was delayed in Hi2P11K15/6
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aggregates (Figure 4.27). The potential to differentiate to neuron-like cells could
further be confirmed by the mRNA expression pattern of neuronal markers. AB2.2
aggregates treated with retinoic acid showed only expression of GFAP. Surprisingly,
Hi2P11K15/6 aggregates expressed both markers. Hi2P11K15/6 cells were the only
cell line that expressed neuronal markers without induction by retinoic acid. So we
could exclude the possibility of Hi2P11K15/6 to be embryonic stem cells. Although
immunofluorescence staining never showed beta3-tubulin- or GFAP-expressing cells,
we could observe an occurrence rate of 7.14% beta3-tubulin-expressing cells by FACS
analysis. In comparison to AB2.2 embryoid bodies, Hi2P11K15/6 aggregates revealed
a higher percental distribution of beat3-tubulin expressing cells (Figure 4.14). Further
investigation on their differentiation potential revealed the presence of vWF and SMA
expressing cells. Due to the fact that Hi2P11K15/6 cells were isolated from the brain
we expected a prevention of cardiomyocyte formation which was confirmed by a lack
of cTnT-expressing cells. We could also see an absence of beating cardiomyocytes
(Figure 4.18) what is attended by the lack of cTnT-expressing cells. Because of
the appearance of neuron-like cells and the absence of beating cardiomyocytes we
concluded that Hi2P11K15/6 cells are restricted to the neuronal lineage.
5.4.3 SSC Clone He2P11K13/5 is Not Resctricted to The Cardiac Lineage
Because of the isolation of He2P11K13/5 from the murine heart we expected a
restriction to the cardiac lineage as seen in CVPC clones. But differentiation studies
revealed the potential to spontaneously form neuron-like cells what was not seen in
CVPC aggregates. Because of the ability of neuronal differentiation we concluded
that these cells are not restricted to the cardiac lineage and are therefore multipotent.
Although the spontaneous formation of neuron-like cells was fewest in He2P11K13/5
aggregates among SSC clone Hi2P11K15/6 and AB2.2 embryoid bodies, they have
the potential for neuronal differentiation (Figure 4.28). The occurrence rate of
He2P11K13/5 aggregates possessing neuron-like cells never passed 10%. We were
not able to classify neuron-like cells as neurons because of the absence of positive
signals during FACS analysis and immunofluorescence microscopy. We assumed that
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the absence of positive signals might be due to the time-dependent appearance of
neuron-like cells. Because neuron-like cells were seen only after passing day 13, we
believe that antibody staining failed because of the absence of neurons. Neuronal
formation proceeded principal in later developmental stages. Indeed, we tried to stain
neuron-like cells on day 20 of aggregate cultivation, but we failed to get meaningful
IF pictures due to the rare occurrence rate of these cells. Immunofluorescence mi-
croscopy revealed the presence of vWF-, cTnT- and SMA-expressing cells. Compared
to CVPC clone A5, He2P11K13/5 aggregates showed a lower beating capacity of
cardiomyocytes. While CVPC clone A5 reached nearly 100 % of aggregates possessing
beating cardiomyocytes on day 13, He2P11K13/5 showed only maximal 65 %.
5.4.4 SSC Aggregates Enhanced Neuron-like Cell Formation by Exposure to Retinoic
Acid
Addition of retinoic acid to SSC aggregates resulted in a decrease in aggregate size
as seen in RA-treated CVPC aggregates and embryoid bodies (Figure 4.17). RA-
treated aggregates seemed to be more compact and cell spreading into periphery
was strongly reduced. Compared to He2P11K13/5 aggregates treated with retinoic
acid, Hi2P11K15/6 aggregates were some bigger. SSC aggregates exposed to high
concentrations of retinoic acid formed a high number of neuron-like cells as seen
in RA-treated CVPC aggregates. The formation of neuron-like cells was enormous
enhanced by addition of retinoic acid. Neuron-like cells were again mainly seen in the
periphery of aggregates and thick tubes radiated away from the center to the periphery
(Figure 4.24). RA-treated Hi2P11K15/6 aggregates possessed neuron-like cells on
day 8, while first appearance of these cells was observed on day 10 in He2P11K13/5.
Compared to AB2.2 embryoid bodies we could recognize a decrease of neuron-like cells
from day 14 on (Figure 4.27). Investigations on the mRNA expression of neuronal
markers revealed that He2P11K13/5 aggregates treated with retinoic acid expressed
GFAP, but not TH as seen in CVPC clone H3 and AB2.2 embryoid bodies. In contrast
RA-treated Hi2P11K15/6 aggregates expressed both markers, but they expressed
these markers also in untreated aggregates, but addition of retinoic acid enhanced the
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expression (Figure 4.30). Again, we were not able to absolutely define these cells as
neuron-like cells, because of the absence of any positive signal for antibodies specific
for neuronal differentiation. Immunofluorescence staining with anti-beta3-tubulin
and anti-GFAP antibodies was negative.
5.4.5 Retinoic Acid is Able To Inhibit Cardiomyogenesis in SSC Aggregates
Rarely we could observe beating cardiomyocytes in SSC aggregates treated with
retinoic acid. The few observed cardiomyocytes hardly contracted and retinoic acid
also seemed to inhibit smooth muscle formation. Immunofluorescence microscopy
showed an absence of any cTnT-expressing cells in SSC aggregates treated with
retinoic acid (Figure 4.20, A). Because Hi2P11K15/6 aggregates never possessed
beating cardiomyocytes even if they were not treated with retinoic acid, we could only
demonstrate the decrease in beating cardiomyocytes on the example of He2P11K13/5
aggregates. Here, we could see a prevention of cardiomyogenesis by a great reduction
of beating aggregates induced by retinoic acid (Figure 4.19). We assume that this
prevention is due to a decrease of Nkx2.5 expression what was demonstrated in CVPC
clone A5.
5.5 FUTURE
CVPCs and SSCs are stable cell lines that can be maintained in an undifferentiated
state and possess self-renewing potential. These cell lines were isolated by two different
methods that resulted in diverse limited differentiation potentials of these cells.
While CVPCs are restricted to the cardiac lineage, SSCs seemed to be multipotent.
Optimizing the isolation method could improve the yield of progenitor cells which are
restricted to cardiac lineage. Proper in vitro investigations of molecular mechanism
involved in CVPC differentiation will help to understand cardiomyocyte development
in the embryonic and adult heart.For this purpose the in vitro embryoid body system is
an adequate tool to mimic early cardiomyogenesis. It remains to be investigated which
signal transduction pathways are involved during cardiomyogenesis and especially in
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cardiomyocyte differentiation. This would further enhance the finding of adequate
cardiomyocyte-stimulating factors to enrich cultures with cardiomyocytes. Insights in
these molecular pathways could reveal how stem cells residing in heart are activated
to differentiate to cardiac cells and how the homing of these cells to the injured
myocardium proceeds. For future in vivo experiments it would be necessary to
understand the differentiation process of CVPCs. Then, it might be possible to inject
exogenous cardiomyocytes into infarcted myocardium and to determine grafting
efficiency as well as their differentiation potential in vivo. So we could determine the
regenerative potential of CVPCs in injured hearts.
6 MATERIAL
6.1 ENZYMES
Table 6.1: Enzymes
Chemical Company
Collagenase Wothington, USA
DNase I, RNase free Fermentas, Lithuania
Pancreatin Sigma, USA
Proteinase K Fluka, CHA
RiboLockRNase Inhibitor Fermentas, Lithuania
RevertAidTM M-MuLV RT New England Biolabs, USA
Taq DNA Polymerase Fermentas, Lithuania
Trypsin Life Technologies, USA
6.2 PROTEINS AND INHIBITOR
Table 6.2: Proteins and Inhibitors
Chemical Company
BMP2/4 R and D Systems
M-LIF Purified from insect cells (Wiedner, 2008)
Recombinant SPARC Sigma, USA
PD98059 Cayman, USA
6.3 GENERAL CHEMICALS
Table 6.3: General Chemicals
Chemical Company
Acetic acid Merch, D
Continued on next page
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Acryl amide BioRad, USA
Agarose Biozyme LE Biozyme, D
Beta-Mercaptoethanol Loba Feinchemie, A
BSA Roth, D
DABCO Sigma, USA
DAPI Invitrogen USA
DNA ladder (gene ruler, 100bp, 1kb) Fermentas Lithuania
dNTPs Fermentas Lithuania
Dimethylsulfoxid (DMSO) Acros, B
Dithiothreitol (DTT) Acros, B
EDTA Acros, B
Ethanol Merch, D
Ethidiumbromide Fluka, CH
Formaldehyde Merck, D
Glycerine Merch, D
Glycin Sigma, USA
Hydrochloric acid (HCl) Acros, B
Lithiumchloride Merck, D
Lipofectamine 2000 Invitrogen USA
Loading dye Fermentas Lithuania
Methanol Merck, D
Magnesiumchloride Fermentas, Lithuania
Magnesiumsulfate Fluka, CH
Mowiol Hoechst, D
Nalgene Filter Nalagene Labware, USA
PCR-buffer without MgCl2 Fermentas, Lithuania
Pepstatin Roche, D
Polyacrylamide Merck, D
Proteinase Inhibitor Roche, D
Reverse Transcriptase Buffer Invitrogen, USA
Sodiumazid Acros, B
Sodiumbicarbonate Sigma, USA
Sodiumhydrogencarbonate Life Technologies, USAA
Sodiumhydrogenphosphate Roth, D
Sodiumhydroxide Merck, D
Continued on next page
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Sodiumthiosulfate Merck, D
Trichloracetic acid Merck, D
Tris Base Life Technologies, USA
Triton X100 Sigma, USA
6.4 CHEMICALS FOR CELL CULTURE
Table 6.4: Chemicals for cell culture
Chemical Company
Beta-Mercaptoethanol Loba, A
D-Glucose Acros, B
DMEM powder Gibco, USA
DMSO Sigma, USA
Fetal Bovine Serum (FBS) HyClone, USA
Fetal Bovine Serum (FBS) Gibco, USA
Fetal Bovine Serum (FBS) Sigma, USA
Gelatine Difco, USA
Glycine Applichem, D
L(+) - Glutamin Gibco, USA
Lipofectamine 2000 Invitrogen, USA
Mitomycin C Acros, B
Penicillin /Streptomycin (P/S) Gibco, CH
Streptomycin Sigma, USA
6.5 KITS
Table 6.5: Kits
Chemical Company
Endo Free Plasmid Maxi Kit Qiagen, D
RNeasy Mini Kit Qiagen, D
Dual Luciferase Reporter System Promega, USA
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6.6 PLASMIDS
6.6.1 RENILLA PLASMID
Figure 6.1: Renilla Plasmid
The pRL-TK vector (here often called as Renilla plasmid) is used as internal control
to determine transfection efficiency. This plasmid carries a Renilla luciferase reporter
gene under the control of T7 promoter that is constantly expressed in the cells. For
selection it additionally carries an Ampicillin resistance gene.
6.6.2 pGL3-BASIC PLASMID
The control pGL3-Basic Vector contains a firefly luciferase gene that is promoterless.
Again we can find an Ampicillin resistance gene.
Figure 6.2: Promega pGL3-Basic Plasmid (E1751)
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6.6.3 NKE24 PLASMID
The NKE24 plasmid is identical to pGL3-Basic vector, but contains an insert of the
Nkx2.5 promoter region in front of the luciferase reporter gene. This vector was
obtained by Dr. Katherine Yutzey (USA).
Figure 6.3: pGL3-Basic vector containing a Nkx2.5 promoter
6.7 PRIMERS
Table 6.6: Primers
Name Direct. Sequence Temp Cycles bp
BMP2 Fwd 5’ - GTTTGTGTTTGGCTTGACGC - 3’ 57.5°C 34 719
Rev 5’ - AGACGTCCTCAGCGAATTTG - 3’
GATA4 Fwd 5’ - GCCTGTATGTAATGCCTGCG - 3’ 53°C 31 500
Rev 5’ - CCGAGCAGGATTTGAAGAGG - 3’
GAPDH Fwd 5’ - CGTCCTTCACCACCATGGAGA- 3’ 55°C 29 300
Rev 5’ - CGGCCATCACGCCACAGTTT- 3’
ILK Fwd 5’ - CTCTGCGGTGGTTGAAAT- 3’ 52.5°C 35 190
Rev 5’ - GAAACATGCATAGTGAAGTGG- 3’
MEF2c Fwd 5’-GGCCATGGTACACCGAGTACAACGAGC-3’ 66°C 34 395
Rev 5’-GGGGATCCCTGTGTTACCTGCACTTGG-3’
Nkx2.5 Fwd 5’ - AGCAACTTCGTGAACTTTG- 3’ 48°C 30 345
Rev 5’ - CCGGCCAGTGTGGA- 3’
Mesp1 Fwd 5’ - AGAAACAGCATCCCAGGAAA- 3’ 52°C 32 346
Rev 5’ - GTGCCTGCTTCATCTTTA- 3’
Isl 1 Fwd 5’ - CGGTGCAAGGACAAGAAA- 3’ 49°C 38 346
Continued on next page
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Rev 5’ - CAATAGGACTGGCTACCA- 3’
MLC1v Fwd 5’ - TCAGGAAGCCCAGGGCAGGC - 3’ 56°C 38 86
Rev 5’ - GGAGTCCGAACCACTCCTTC - 3’
GFAP Fwd 5’ - AGGAGCCAGCAGAGGCAGGG - 3’ 72°C 35 852
Rev 5’ - CTTGGCTTGGCGGAGCAGCT - 3’
TBX5 Fwd 5’ - GTTCCAGCACGGAGCACCCC - 3’ 55°C 31 422
Rev 5’ - CCCGCACTGCCTGACCACAG - 3’
TH Fwd 5’ - CGTCTCAGAGCAGGATACCAAGCAG - 3’ 71°C 35 835
Rev 5’ - CAGTAGACCGGCCACGGGTC - 3’
6.8 ANTIBODIES
Table 6.7: Antibodies
Chemical Company
anti-rabbit Alexa Fluor 647 Conjugate Cell Signaling 4414
anti-mouse Alexa Fluor 488 Conjugate Cell Signaling 4408
anti-mouse Troponin T-C (CT3) Santa Cruz Biotechnology I2208
anti-mouse FITC Dianova 715-095-151
Human BMP-2/4 R and D Systems MAB3552
Mouse LIF R and D Systems AF449
anti-rabbit FITC Jackson Labs 711-095-152
anti-mouse Smooth muscle actin Sigma A2547
SPARC Santa Cruz 25574 /Sigma S5174
anti-rabbit Von Willebrand Factor Sigma F-3520
anti-mouse Beta-3-tubulin (TU-20) Cell Signaling 4466S
anti-rabbit Glial fibrillary protein (GFAP) Sigma Aldrich SL09462
FOXA2/HNF3beta Cell Signaling 3143S
6.9 CELL LINES
6.9.1 SNL76/7- Fibroblasts
Allan Bradley established the murine SNL76/7 fibroblast cell line, which derives from
the murine STO fibroblast cell line and contains a neomycin-resistence and LIF gene
(McMahon and Bradley, 1990).
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6.9.2 Bacteria Strain XL1-Blue
Bacteria strain XL1-Blue was used to multiply different plasmids (Stratagene, USA).
6.9.3 Embryonic stem cells
AB2.2
The embryonic stem cell line AB2.2 originates from 129v mice and was isolated by
Allan Bradley (Soriano et al., 1991).
DC6
This cell line overexpresses Desmin and was obtained by Sonja Puz (Puz, 1999).
6.9.4 Cardiovascular progenitor cells
The CVPC cell line was isolated from the heart tissue of neonatal HDAC1 +/- mice
(N1-2 neoR) by Georg Weitzer and Wolfgang Weber. Because of the presence of
a neomycin resistance gene in one allel of the HDAC1 locus cells are resistant to
neomycin and neomycin analogs like G418. Isolated cells were co-cultured with the
embryonic stem cells AB2.2 and feeder cells for 10 passages according to a 3T3 proto-
col. Selection with G418 resulted in survival of cells carrying a neomycin resistance.
The survived cells are named cardiovascular progenitor cells (CVPCs) and consists of
eleven subclones (A3, A5, B3, B5, C3, D3, D5, E3, F3, G3 and H3). In this study
CVPC clones A5 and H3 were used.
A5-CSX
This CVPC cell line contains an EGFP reporter gene under the control of Nkx2.5
promoter region. The pCsx-EGFP-PP-DT plasmid was inserted into the Nkx2.5
locus of A5 cells by homologue recombination (Gottschamel, 2010)
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6.9.5 Somatic stem cells
The somatic stem cell lines (SSCs) were isolated from several tissues of neonatal and
adult mice. Single clones were obtained from the brain, pancreas and the heart of
wildtype mice. This isolation method uses embryonic stem cells (Tag3) carrying the
selection marker thymidine kinase. Isolated cells were co-cultured with ESCs (Tag3)
and feeder cells for 10 passages according to a 3T3 protocol. Negative selection was
performed with Ganciclovir for 2x4 days and resulted in the isolation of SSC clones.
In this diploma thesis, He2P11K13/5 (isolated from the heart) and Hi2P11K15/6
(isolated from the brain) cells were used for experiments.
7 METHODS
7.1 CELL CULTURE
7.1.1 Washing of glass pipettes
Because ESCs and CVPCs are sensitive to any kind of contamination, glass pipettes
are washed only with hypochlorite and tapwater to avoid contamination with soap
and other organic substances. Cotton plugs of used glass pipettes is removed and
pipettes are put into vessels containing a mixture of hypochlorite and tapwater.
Glass pipettes are then washed with tapwater for at least four hours and are kept in
milliQ-H2O overnight. The next day pipettes are dried at 60°C for about 3 hours and
are stuffed with new cotton plugs. They are placed into pipette boxes and backed at
180°C for 8 to 10 hours.
7.1.2 Washing of cell culture glass ware
Used glass ware for tissue culture work is filled with tapwater and hypochlorite. After
15 to 30 minutes glass ware is rinsed out with tapwater until no hypochlorite is left.
Glass ware is rinsed out with milliQ-H2O to ensure no tapwater is left. It is then
filled with milliQ-H2O and left overnight. The next day glass ware is dried and
autoclaved at 120°C and 1 bar.
Other tissue culture appliances are also washed with hypochlorite and tapwater,
followed by rinsing them with milliQ-H2O. It is important that they never come in
contact with soap.
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7.2 BUFFER AND SOLUTIONS
10x PBS (phosphate buffered saline)
1.37 M NaCl
14.7 mM KCl
78.1 mM Na2HPO4x7H2O
26.8 mM KH2PO4
80g NaCl, 2g KCl, 10,72g Na2HPO4x7H2O and 2g KH2PO4 was dissolved in 800ml
MilliQ water and pH was adjusted to 7.2 with a saturated Na2HPO4x7H2O solution.
After the buffer is filled up to the 1l mark with MilliQ the solution is sterile filtered
(Nalgene Filter, Nalgene Membrane; 0.22µm pore width) and stored at room temper-
ature.
1x PBS
10x PBS is diluted 1:10 with MilliQ and stored at room temperature.
100x GPS (Glutamine-Penecillin-Streptomycin)
4.25 g NaCl
1.5 g Penicillin
2.5 g Streptomycin
14.6 g L-(+)-Glutamine
Ingredients are dissolved in 500 ml MilliQ and sterile filtered. Aliquots of 40 ml are
transferred into 50 ml Falcon tubes and stored at -20°C. Aliquot in use is stored at
4°C (to dissolve the pellet during thawing it is commended to mix and put it on 37°C
till pellet is completely thawed)
100x ß-Mercaptoethanol
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200 ml 1x PBS
144 µl beta-Mercaptoethanol
Sterile filtration and aliquoting in 50ml Falcon tubes. Storage at -20°C. Aliquot in
use is stored at 4°C.
Trypsin
3.5g NaCl
0.5g D-Glucose
0.09g Na2HPO4x7H2O
0.185g KCl
0.12g KH2PO4
0.2g EDTA
1.25g Trypsin
1.5g Tris Base
Ingredients were dissolved in 500ml MilliQ water and pH was adjusted to 7.6 with
concentrated HCl. The solution is sterile filtered and stored at -20°C. Aliquot in use
is stored at 4°C.
1% gelatin stock solution
10g gelatin is dissolved in 1l of MilliQ water and autoclaved. Storage at room tem-
perature
0.1% gelatin solution
1x stock solution is diluted 1:10 with MilliQ and stored at room temperature.
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Dulbecco’s Modified Eagle Medium (DMEM)
4.5 l MilliQ are poured into a 5 l Erlenmeyer flask and 66.9 g of DMEM are added
(magnetic stirrer). 18.5 g (3.7 g/l) NaHCO3 are added, the pH of 7.4 is adjusted
with concentrated HCl and the flask is filled up to the 5 l mark with MilliQ. The
medium is sterile filtered and stored at 4°C. Aliquots of 3 ml are pipetted into a 6
well culture dish and incubated at 37°C, 5% CO2. These aliquots are checked for
bacterial growth or other contamination daily until the medium is used.
Culture media
M15Hi medium M15Si medium M10Gi medium Freezing medium
15% HyClone FBS 15% Sigma FBS 10% Gibco FBS 60% DMEM
1% beta- Mercap-
toethanol
1% beta- Mercap-
toethanol
1% beta- Mercap-
toethanol
20% FBS
1% GPS 1% GPS 1% GPS 20% DMSO
83% DMEM 83% DMEM 88% DMEM
Gelatin coating of cell culture plates
To obtain a adequate surface matrix for cells to attach we coat cell culture plates
with 0,1% gelatine solution two hours prior to use. Before cells are added remaining
solution is aspirated.
7.3 SNL76/7
7.3.1 Thawing of SNL76/7
Aliquots are stored in cryotubes in liquid nitrogen. For thawing aliquots are put into
a 37°C water bath and thawed until a tiny ice cube is left. The tube is disinfected
with 70% ethanol, put into the lamina flow and flamed at a Bunsen burner. The total
volume of the cryotube is transferred into a 50ml Falcon tube and M10Gi medium is
added drop by drop until to the 12.5ml mark. After each drop the tube is shaked
carefully to ensure consistent dispersion of M10Gi medium. Drops were added not
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too fast and not too slow. When added too fast cell will burst due to osmotic shock
and when added too slow cells are kept too long in DMSO rich medium what will
kill them. After addition of M10Gi the Falcon tube is centrifuged for 7 minutes at
1000rpm at room temperature (Heraeus Biofuge, swing out buckets) and the pellet
is resuspended in 1ml M10Gi and transferred onto bacterial dishes. Residual cells
are washed out with another 3ml M10Gi and solution is added to the dish. SNL76/7
fibroblasts are kept at 37°C at 5%CO2.
7.3.2 Cultivation of SNL76/7
Cells are cultivated at 37°C at 5%CO2. Medium change is often not necessary,
but must be done when pH indicator switches to orange. If the cells are confluent
they have to be splitted onto new dishes. Cells were generally splitted on Mondays
in a ratio of 1:6 and on Fridays 1:3. Before splitting cells are washed with 4ml
1xPBS to get rid of any traces of medium which will inhibit trypsin action. For
detaching SNL76/7 cells from the matrix 2ml trypsin is added for five minutes at
37°C. Detachment is checked under the light microscope. Round shaped cells are
indicators for detachment and trypsin can be inactivated by adding fresh M10Gi. For
1:3 splitting trysin is inactivated by adding 3ml of M10Gi and 1ml of this solution is
transferred onto new dishes containing already 7ml M10Gi medium.
7.3.3 Freezing of SNL76/7
Confluent cells are washed with 1xPBS twice and 0.7ml trypsin is added for 7 minutes
at 37°C. Trypsin is inactivated by 2ml M10Gi and cell suspension is transferred into
a 15ml Falcon tube. 2.7ml freezing medium (FBS Gibco) are added drop by drop.
Content is transferred into two cryotubes and stored for 48 hours in a tightly sealed
styropor box at -80°C. Finally cryotubes can be transferred to a liquid nitrogen tank.
Freezing medium consists of 60% DMEM, 20% Gibco FBS Serum and 20% DMSO.
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7.3.4 Generation of feeder cells
One confluent SNL76/7 10cm plate is sufficient to obtain two 24 well plates. Medium
of a confluent plate is aspirated until 4ml is left. Therefore it is the best to use a
glass pipette and take up the whole medium and return 4ml to the cells. For mitotic
inactivation of SNL76/7 fibroblast 80ml Mitomycin C is added for 3-4 hours at 37°C
and 5%CO2. Supernatant is removed and cells are washed twice with 1xPBS before
addition of trypsin for five minutes at 37°C. Trypsin is inactivated after addition of
5ml M10Gi medium. Cells are pooled in a 50ml Falcon tube and centrifuged for 7
minutes at 1000rpm (Heraeus Biofuge, swing out buckets). Pellet is resuspended in
10ml M10Gi medium and cell number is determined with a cell counter chamber. Cells
are diluted in a 50ml Falcon or when necessary in a 150ml glass bottle with M10Gi
until a cell concentration of 35 x 104 cells/ml is achieved. Feeder cells are transferred
onto gelatine-coated culture plates and stored at 37°C and 5%CO2. Feeders can be
used the next day and up to two weeks and have to be fed once a week with M10Gi.
Table 7.2: seeding of feeder cells
Culture plate ml transferred
96 well plate 100 µl / well
24 well plate 500 µl /well
6 well plate 2 ml/ well
6 cm dish 4 ml / well
10 cm dish 12 ml / well
7.4 EMBRYONIC STEM CELLS, CARDIOVASCULAR PROGENITOR CELLS
AND SOMATIC STEM CELLS
7.4.1 Thawing of ESC, CVPC and SSC
Before thawing feeder cells must be fed with M15Hi medium 2 hours prior to adding
thawed cells. Selected cryotubes are removed from the liquid nitrogen tank and
put in a 37°C water bath until a tiny ice cube is left. Tube is disinfected with 70%
ethanol and flamed before content is transferred into a 15ml Falcon tube. M15Hi
medium is added drop by drop under pivoting until the 12.5ml mark is reached.
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Drops were added not too fast and not too slow. When added too fast cell will burst
due to osmotic shock and when added too slow cells are kept too long in DMSO
rich medium what will kill them. After addition of M15Hi Falcon is centrifuged for
7 minutes at 1000rpm at room temperature (Heraeus Biofuge, swing out buckets)
and pellet is resuspended in 1ml of pre-fed feeder cell medium and transferred back
onto the feeder cells. Cells are kept at 37°C at 5%CO2 and must be fed after 24 hours.
7.4.2 Culture of ESCs, SSCs and CVPCs
The cells are cultivated at 37°C and 5% CO2 and are fed every 24 hours with fresh
M15Hi. To keep the cells in an undifferentiated state they are co-cultured with feeder
cells expressing leukemia inhibitory factor (LIF) to maintain their self-renewing po-
tential. Cells cultivated in 24-well plates are fed with 1 ml to 2 ml M15Hi depending
on their confluence. Cells must be split when the well is confluent.
7.4.3 Splitting of ESCs, SSCs and CVPCs
Feeder cells and ESCs (CVPCs/ SSCs) must be fed with fresh M15Hi two hours
prior to splitting. The appropriate number of Feeder-wells on which the ESCs (SSCs/
CVPCs) are cultivated after splitting are fed with 2ml M15Hi to enrich the medium
with enough LIF. ESCs (SSCs/ CVPCs) are fed with 0.5ml M15Hi. After two hours
the medium of the ESCs (SSCs/ CVPCs) is aspirated and the cells are washed
once with 1x PBS. After removal of PBS by aspiration, trypsin is added to the cells
(100µl/48 well; 200µl/24 well; 800µl/6 well; 2ml/10cm) and the cells are placed at
37°C and 5% CO2. After an incubation time of 20 minutes trypsin is inactivated by
resuspending the cells in medium from the pre-fed feeder cells (at least thrice the
amount of trypsin is used: 500µl/100µl trypsin; 1ml/200µl trypsin). In general cells
are splitted in ratios of 1:2 or 1: 3 and the appropriate volume of this suspension is
transferred back onto the new feeder cells. Splitting ratio depends on the confluence
of the cells.
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7.4.4 Freezing of ESCs, CVPCs and SSCs
Cells have to be fed two hours prior to freezing. Cells grown on 24 wells are washed
with 1xPBS and 200µl trypsin is added to detach cells from surface for 20 minutes at
37°C and 5%CO2. To inactivate trypsin 1ml M15Hi is added to the cells. Freezing
medium (FBS HyClone) is added in a 1:1 ratio therefore a volume of 1200µl is added
to the cells drop by drop. For the first 200µl a 200µl pipette is used and one drop
after another is added carefully. After each drop the well is shaked carefully. Next
a 1000µl pipette is used and again the freezing medium is added drop by drop. To
ensure a homogenous distribution the pipette is used to stir within the well carefully.
Each 800µl of the suspension are transferred into a cryotube and stored for 48 hours
in a tightly sealed styroform box in a -80°C freezer. After 48 hours cryotubes are
transferred into liquid nitrogen tank.
Freezing medium consists of 60% DMEM, 20% HyClone FBS Serum and 20% DMSO.
7.4.5 Generation of Embryoid Body (EB) like aggregates
ESCs/CVPCs/SSCs cultured on feeder cells in 24 wells must be split 1:2 24 hours
before aggregate formation to be in log phase. The cells are fed with 1ml fresh M15Si
two hours prior to EB/CB formation and 6 well plates are coated with gelatin (0,1%).
After two hours cells are washed with 1x PBS and 200µl of trypsin are added to the
cells for 20 minutes at 37°C and 5% CO2. Cells are resuspended in 800µl M15Si
to inactivate trypsin. To get rid of the feeder cells, which would disturb aggregate
formation, the suspension is transferred to the gelatin coated 6 well and incubated
for 45 minutes to 1 hour at 37°C and 5% CO2. Because the feeder cells adhere
faster than embryonic stem cells (SSCs/CVPCs) it is possible to separate the ESC
(CVPCs/SSCs) from feeder cells by preabsorption. The supernatant is transferred to
a 50ml Falcon and is expanded with M15Si to a final concentration of about 4.5 x
104 cells/ml. Sterile bacteria plates are filled with autoclaved milliQ-H2O and each
20µl of the all supernatant is dropped on the lid of plates until the lid is densely
covered with drops. The lid is put back carefully onto the dish filled with water,
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thereby creating hanging drops. The plates are incubated at 37°C and 5% CO2 for
4.7 days and then rinsed with 6 ml M15Si onto gelled 10 cm cell culture plates. The
aggregates are dispersed well and with care and incubated at 37°C and 5% CO2.
7.4.6 Culture of aggregates
Aggregates are fed on day 7 for the first time. From then on they get fed on every
third day. Thereby the medium is partially removed and an appropriate volume of
fresh M15Si is added.
Feeding protocol:
Table 7.3: feeding protocol
day old medium kept fresh medium added old medium kept fresh medium added
10 cm culture plate 60 mm culture plate
7 3 ml 8 ml 1.5 ml 4 ml
10 3 ml 8 ml 1.5 ml 4 ml
13 4 ml 10 ml 2 ml 5 ml
16 4 ml 10 ml 2 ml 5 ml
19 4 ml 10 ml 2 ml 5 ml
22 4 ml 10 ml 2 ml 5 ml
25 5 ml 12 ml 2.5 ml 6 ml
28 5 ml 12 ml 2.5 ml 6 ml
31 5 ml 12 ml 2.5 ml 6 ml
7.5 FIXATION AND IMMUNOFLUORESCENCE
7.5.1 Fixation
Embryoid body-like aggregates grown onto gelatin-coated cover slips were fixed on
day 20 of cultivation. Therefore cover slips were transferred carefully into a 6 well,
which was prior treated with a hot forceps to create protuberances. The resulting
unevenness makes it easier to remove cover slips later from the well. Gently, 2 ml of
1x PBS are added and cells were washed. Again 1xPBS is added but this time for
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two minutes and on ice. During this time period cover slips were transported to the
lab carefully. 1x PBS is aspirated thereby avoiding to get too close to the aggregates
and 2 ml of EtOH (-20°C) is added carefully drop by drop. It is important to do
not drop directly onto cells, but to rinse EtOH along the edge into the wells. Cover
slips are stored for 20 minutes at -20°C. After that 800µl ddH2O are dropped to the
aggregates under pivoting the well thereby a concentration of 70% EtOH is reached.
Again cover slips are stored at -20°C for 20 minutes. Fixed aggregates are stored in
70% EtOH at 4°C and are ready to use for immunofluorescence staining. To avoid
evaporation wells are sealed with parafilm.
7.5.2 Immunofluorescence-method 1
70% EtOH is aspirated and cover slips are washed three times with 2ml 1x PBS for
five minutes. It is important to rinse any liquid gently and slowly along the edge
of the wells to avoid disruptions of aggregates. First antibody is diluted (generally
1:200) with 1x PBS and 100µl of the antibody solution is dropped onto the lid of a
6 well plate. Next cover slips are put onto these antibody drops for 1h 30 minutes.
To avoid drying small wet pieces of paper are put into the wells and the plate is put
into a wet chamber. Cover slips are washed three times with 2ml 1x PBS for ten
minutes. Secondary antibody is diluted and also dropped onto the lid of a culture
plate. Cover slips are kept for 45 minutes on the antibody solution in a wet chamber.
Cover slips are again washed with 1x PBS for ten minutes and DAPI is added in a
concentration of 1:1000 for 5 minutes. To get rid of DAPI aggregates were washed
twice with 1xPBS for 10 minutes. Cover slips are fixed onto a microscope slide with
mowiol (40-80µl depending on the size of cover slips). Mowiol may be shortly heated
to 37°C before use. Cover slips and slides are dried over night in the dark. The next
day the edges of the cover slips are sealed by nail polish and stored at 4°C.
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7.5.3 Fixation and Immunofluorescence-method 2
Appropriate cover slips are selected for immunofluorescence. Cover slips were trans-
ferred carefully into a 6 well, which was prior treated with a hot forceps to create
protuberances. Embryoid body -like aggregates are washed with 1x PBS and were
fixed in 4% Paraformaldehyde (2ml) for 20 minutes at room temperature under
pivoting. Cover slips were washed twice with 1x PBS to get rid of paraformaldehyde.
Next 0.1% Saponin (1ml) is added to the aggregates for 20 minutes at room tem-
perature under pivoting to permeabilize cells. Again aggregates were washed twice
with 1x PBS. For blocking we used 2% BSA in PBS ( 1ml) for 10 minutes at room
temperature. First antibody is diluted in 2% BSA/PBS as prescribed 100µl of the
antibody solution is dropped onto the lid of a 6 Well plate. Next cover slips are put
onto these antibody drops for 1 hour at 4°C. To avoid drying small wet pieces of
paper are put into the wells and the plate is put into a wet chamber. Cover slips are
washed three times with 2ml 1xPBS for ten minutes under gentle pivoting. Secondary
antibody is diluted and also dropped onto the lid of a culture plate. Cover slips are
kept for 1 hour on the antibody solution in a wet chamber. Cover slips are again
washed with 1x PBS for ten minutes and DAPI is added in a concentration of 1:1000
for 5 minutes. Cover slips are washed twice with 1x PBS for 15 minutes. Cover slips
are fixed onto a microscope slide with mowiol (40-80µl depending on the size of cover
slips). Cover slips and slides are dried over night in the dark. The next day the edges
of the cover slips are sealed by nail polish and stored at 4°C. To visualize fluorescent
staining a LSM - Meta 510 (Zeiss) Microscope is used.
Mowiol
6 g Glycerin
2.6 g Mowiol 2-88
5 % DABCO
6 ml ddH2O
The ingredients are mixed together and incubated at room temperature for 2 hours.
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Addition of 12 ml 0.2M Tris/HCl pH 8.5 was followed and incubation for 10 minutes
at 50°C is performed. Centrifugation for 15 minutes at 5000 rpm was continued and
aliquots are stored at -20°C.
7.6 mRNA ISOLATION FROM CELLS (ESC/SSC/CVPC) with RNeasy Mini Kit
(Quiagen)
7.6.1 RNeasy Mini Kit
Before RNA isolation the bench is carefully cleaned with soap and ethanol to get rid
of RNases as much as possible. During the whole isolation process a set of pipettes is
used uniquely for RNA. Cells are fed with medium 2 hours prior to isolation. Cells are
washed with ice cold 1x PBS twice and are scraped with a scraper. The supernatant
is transferred into a 15 ml Falcon tube and centrifuged for 5 minutes at 1000 rpm.
The supernatant is aspirated and the pellet is resuspended in 600µl RLT buffer - beta-
mercaptoethanol (100:1). Suspension is loaded onto the shreeder column (violet) and
centrifuged for 2 minutes at 14000 rpm and at room temperature. 70% EtOH is
added in a ratio of 1:1 (600µl) to the flow through and mixed by pipetting. 600µl of
this suspension is transferred onto a RNeasy Mini Spin Column (pink) and results
in RNA binding to the column. Column is centrifuged for 15 seconds at 14000 rpm
and flow through is discarded. The remaining 600µl suspension is loaded onto the
same column and centrifugation step is repeated. 700µl RW1 buffer is loaded onto
the column and is centrifuged for 15 seconds at 14000 rpm. Flow through and tube is
discarded and column is put in a fresh tube. 500µl RPE (with EtOH) is added and
centrifuged for 15 seconds at 14000rpm. Again flow through and tube is discarded.
RPE treatment is once again performed, but this time centrifugation step proceeds
for 2 minutes. Column is now put into a 1.5 ml eppendorf tube and 30µl RNase free
water was added directly onto the membrane. To elute RNA, water was incubated
for 1 minute and afterwards column is centrifuged for 1 minute at 14000 rpm.
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7.6.2 DNA digestion
For DNA digestion, 3.75 µl DNase I buffer and 3.75 µl DNase I buffer are added to
the eluate and the tube is kept at 37°C for 30 minutes. To stop digestion 3.75 µl
EDTA are added to the tube and is kept for 10 minutes at 65°C on a shaker. RNA
eluate is stored at -80°C. DNA digestion was controlled by a GAPDH PCR. No bands
visible at 300bp (GAPDH) indicate a successful DNA digestion.
7.6.3 Reverse Transcription
To determine RNA concentration we performed a Nanodrop measurement.Ideally the
concentration should be 0.5 µg/µl or larger. If the concentration of RNA was lower
than 0.5 µg/µl a different procedure was used.
1. c < 0.5 µg/µl
2. c = 0.5 µg/µl; c > 0.5 µg/µl
Ad 1. RNA concentrations lower than 0.5 µg/µl:
Because the RNA concentration is too low it is necessary to adopt the whole volume
of the mRNA solution. So we deal now with a volume of 70 µl instead of 50 µl.
This means a factor of 1.4 which is multiplied with substances applied during RT to
maintain the ratio. Whole volume of mRNA solution is used. 1.4 µl d(T) are added
to the sample for 10 minutes at 70°C, followed by incubation on ice for 3 minutes.
Tube is centrifuged for 30 seconds at 13000 rpm. Reverse transcription - Mix is added
to the sample and an end volume of 25.9 µl is reached. RT - Mix is incubated for 2
minutes at 42°C. After this 1.4 µl Revert Aid Reverse Transcriptase is added and
incubated for 50 minutes at 42°C. Next the sample was incubated for 15 minutes
at 70°C and put on ice for another 5 minutes. Tube is centrifuged for 2 minutes at
13000 rpm and stored at -20°C.
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Ad 2. RNA concentration is about 0.5 µg/µl
A volume of 29.5 µl is used. If concentrations are much higher than 0.5 µg/µl samples
have to be diluted to the correct concentration with RNase free water. 1 µl d(T)
are added to the sample for 10 minutes at 70°C and incubated on ice for 3 minutes.
Centrifugation is performed for 30 seconds at 13000 rpm and RT-Mix is added for 2
minutes at 42°C. 1 µl Revert Aid Reverse Transcriptase is added and incubated for 50
minutes at 42°C followed by incubation at 70°C for 15 minutes. Before centrifugation
at 13000 rpm for 2 minutes samples are kept on ice for 5 minutes. Storage at -20°C.
Table 7.4: RT-mix
Ad 1. RT-Mix Ad 2. RT-Mix
14 µl 5x Buffer 10 µl 5x Buffer
7µl 0.1M DTT 5µl 0.1M DTT
2.1µl RNase Inhibitor 1.5µl RNase Inhibitor
2.8µl 10mM dNTPs 2µl 10mM dNTPs
End-Volume: 25.9µl End-Volume: 18.5µl
For further RT-PCR analysis concentrations of samples has to be balanced for equal
amounts of cDNA. Therefore, it is necessary to balance the concentration of the
mRNA product of the house keeping gene GAPDH.
7.7 PCR
38.75 µl dH2O
5 µl 10x buffer (Fermentas EP0402)
3 µl 25mM MgCl (Fermentas EP0402)
1 µl 10mM dNTPs (Fermentas R0192)
0.5 µl Forward primer (Vienna Bio Tec)
0.5 µl Reverse primer (Vienna Bio Tec)
0.25 µl Taq Polymerase (Fermentas EP0402)
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Dependent on the number of samples applied for PCR a multiple of the mastermix is
made. Aliquots of 49µl are added to each PCR sample and 1µl of sample DNA is
added. PCR tubes (Klösch) are gently mixed and spinned followed by placing the
tubes in a Biometra T-Personal PCR machine.
PCR - Program:
94°C for 60 seconds
94°C for 45 seconds
x °C for 45 seconds (usually 50°C < x < 66°C depending on primers)
72°C for 60 seconds
Repeating step 2-4 for 28-39 cycles (depending on TM of primers)
72°C for 240 seconds
4°C
7.8 FACS
7.8.1 Fixation
Embryoid body-like aggregates are grown onto gelatin-coated culture plates. Be-
fore staining with adequate antibodies aggregates have to be separated into single
cell suspension and fixed. Therefore aggregates are washed twice with 1xPBS and
a mixture of Trypsin, Collagenase and Pancreatin is added (1.5 ml) for 20 min-
utes at 37°C. 8 ml M10Gi is added to inactivate trypsin and cells are pooled in
a 50 ml Falcon. This Falcon is then centrifuged at 1200 rpm for 2 minutes and
the supernatant is collected in a fresh Falcon. The pellet is then resuspended in
Trypsin/Collagenase/Pancreatin (2 ml) and incubated for 10 minutes at 37°C. 8
ml of M10Gi are added and the Falcon is centrifuged at 1200 rpm for 1 minutes.
The supernatant is pooled with the previous collected supernatant. The pellet is
resuspended in 1 ml Trypsin/Collagenase/Pancreatin for 7 minutes at 37°C. The cells
are resuspended in 5 ml M10Gi and are centrifuged for 1 minute at 1200 rpm. The
supernatant is pooled again followed by centrifugation for 5 minutes at 1200 rpm.
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The pellet is once washed with 1x PBS and centrifuged again. Finally, the cells are
fixed in 4% paraformaldehyde and the cell number is determined. Therefore Falcon
is rotated for 20 minutes at room temperature and stored at 4°C.
Trypsin/Collagenase/Pancreatin mix:
40 ml Trypsin
20 mg Collagenase
24 mg Pancreatin
4% Paraformaldehyde:
8.648 ml 37% Formaldehyde
71.348 ml 1x PBS
7.8.2 Staining procedure
6x 106 cells per cell line are transferred into an eppendorf tube and are centrifuged for
5 minutes at 1200 rpm. Cells are washed with 1 ml 1x PBS and are centrifuged for 5
minutes at 1200 rpm. This washing step is repeated twice followed by resuspending
the cell pellet in 0.15% Saponin in PBS (500µl) and incubating the pellet for 20
minutes at room temperature under pivoting. After 20 minutes cells are centrifuged
for 5 minutes at 1200 rpm. To block unspecific bindings cells were incubated in 500µl
2% BSA in PBS for 10 minutes at room temperature under pivoting. A supplemental
volume of 1xPBS is added to split whole volume into tubes with aliquots of 100µl
(for example: addition of 300µl 1xPBS results in splitting the volume into 8 tubes
with 100µl). Tubes are centrifuged for 5 minutes at 1000 rpm and primary antibody
in 2%BSA/PBS (100µl) is added for 1 hour under pivoting or over night at 4°C,
respectively. For control we used samples that are not stained with primary, but with
secondary antibodies to determine background staining. Next, tubes are centrifuges
for 8 minutes at 1200 rpm and supernatant is aspirated. Cells are washed with 1x
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PBS and centrifuged for 5 minutes at 1200 rpm for three times. Secondary antibody
diluted in 2%BSA/PBS is added for 30 to 45 minutes in the dark or overnight under
pivoting, respectively. Centrifugation of 8 minutes at 1200 rpm is followed. Again
the pellet was washed for three times (5’ 1200rpm). Finally, the pellet is resuspended
in 300 to 500µl 1xPBS and FACS analysis is performed.
For staining we used following primary and secondary antibodies in concentrations
mentioned below:
Table 7.5: Antibody Dilutions
Antibody Dilution
Anti-rabbit FOXA2 1:200
Anti-rabbit GFAP 1:200
Anti-rabbit vWF 1:200
Anti-mouse Beta3-tubulin 1:200
Anti-mouse SMA 1:200
Anti-mouse cTnT 1:200
2nd: anti-mouse Alexa Fluor 488 1:500
2nd: anti rabbit Alexa Fluor 647 1:500
7.9 TRANSIENTE TRANSFECTION
7.9.1 Plasmid preparation
E.coli transformed with distinct plasmids are embedded in glycerol and shock-frozen
in liquid nitrogen for long-term storage at -80°C. E.coli carrying the plasmid of interest
are transferred to an antibiotic-selective LB-agar plate with a toothpick. For isolation
and expansion of pGl3b-Basic (AmpR), NKE 24 (Nkx-luc, AmpR) and TOPFLASH
(AmpR) plasmids LB Amp plates are used and E.coli carrying these plasmids are
incubated overnight at 37°C. The next day plates can be stored for several weeks
at 4°C by sealing it with parafilm. For plasmid preparation the Endofree Plasmid
Maxi Kit is used. A single E. coli colony is picked with a toothpick and transferred
into a cuvette tube containing 3ml Amp-selective LB medium (50mg/ml Ampicillin).
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E.coli are incubated for 4 hours at 37°C under shaking. After 4 hours the content
is transferred into an Erlenmayer flask and 150 ml Amp LB medium is added and
incubation proceeds overnight at 37°C under shaking.
The overnight-culture is transferred into a 50 ml Falcon the next day and is centrifuged
for 15 minutes at 4000 rpm at 4°C. The pellet is then resuspended well in ice cold 10
ml buffer P1. 10 ml buffer P2 is added and Falcon is inverted three times followed
by incubation of 5 minutes at room temperature to shear genomic DNA. Further 10
ml ice cold buffer P3 is added and Falcon is inverted eight times. The suspension is
transferred in a Qiagen Cartridge and kept for 10 minutes at room temperature. The
supernatant is pushed through the cartridge into a fresh Falcon and 2.5 ml ER buffer
is added. Falcon is inverted ten times and kept on ice for 30 minutes. A Qiagen tip
500 is equilibrated with 10 ml QBT. The filtered lysate is transferred into the Qiagen
tip 500 and the column is emptied by gravity flow. The Qiagen tip 500 is washed
twice with 30 ml buffer QC. DNA is eluated into a new flask by adding 15 ml buffer
QN and 10.5 ml Isopropanol is added to the eluate. The eluate is mixed well and
centrifuged at 13000 rpm for 30 minutes at 4°C. The supernatant is discarded and the
pellet is resuspended in 5 ml 70% EtOH and is centrifuged for 10 minutes at 13000
rpm at 4°C. Again the supernatant is discarded and the pellet is dried for 15 minutes.
Next, the pellet is resuspended in TE-buffer and stored at -20°C. DNA concentration
is measured by using a NanoDrop machine. Plasmids are ready to use for transfection.
Ampicillin Stock 1000x
250 mg Ampicillin
5 ml destilled water
steril filtered and storage at -20°C
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7.9.2 Transfection of CVPCs
Lipofectamine Transfection on undifferentiated CVPCs
One day before transfection, cells grown on 24 well with feeders are trypsinized
for 20 minutes at 37°C. This is followed by preabsorption of cells for 1 hour at
37°C to get rid of feeder cells. Feeder cells attach faster to the surface compared
to CVPCs, therefore we are able to separate these cells easily from each other. 6 x
104 cardiovascular progenitor cells are seeded onto gelatin-coated 48 wells in M15Hy
medium. The next day transient transfection is performed using lipofectamine 2000.
Therefore cells are washed once with 1x PBS and 300 µl transfection medium is added
for 2 hours at 37°C. During this incubation time Mastermixes and Lipofectamine
Mixes are generated. Lipofectamine is added in a ratio of 1:50 to a DMEM and
Glutamine solution followed by an incubation of 5 minutes at room temperature.
Mastermix 1 and Lipofectamine Mix 1 as well as Mastermix 2 and Lipofectamine 2
are pooled and incubated for 20 minutes at room temperature to allow the generation
of Lipofectamine-DNA complexes. After the two hours 60µl of these complexes are
added to the cells for 3 hours at 37°C. During this incubation time complexes are
able to enter the cells and deliver the DNA. Then the medium is aspirated completely
and 300 µl fresh M15Hy medium is added to each well.
Transfection medium:
83 % DMEM
15 % HyClone
1 % Glutamine
1 % Beta-Mercaptoethanol
Mastermix 1 Mastermix 2
1µg pGL3b DNA 1µg NKE24 DNA
10ng Renilla DNA 10ng Renilla DNA
Continued on next page
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DMEM (99%) + Glutamine (1%) DMEM (99%) + Glutamine (1%)
Lipofectamine Mix 1 Lipofectamine Mix 2
Lipofectamine Lipofectamine
DMEM (99%) + Glutamine (1%) DMEM (99%) + Glutamine (1%)
Lipofectamine Transfection on differentiated embryoid body-like CVPCs aggregates
Embryoid body -like aggregates of CVPCs are generated by using the hanging drop
procedure (4.5 x 104 cells/ml). Five days after hanging drop cultivation aggregates
were rinsed onto gelatin-coated culture plates with M15Si medium. On day 9 of
cultivation cells are washed with 1x PBS and 2 ml trypsin is added for 20 minutes at
37°C. 6 x 104 cells are seeded onto gelatin-coated 48 well plate and after 24 hours tran-
sient transfection using lipofectamine 2000 is performed (see undifferentiated CVPCs).
Luciferase assay
Here we use the Promega Dual-Luciferase Reporter assay System Kit. Cells grown on
culture plates are washed once with 1xPBS and supernatant is aspirated. 1x Passive
Lysis Buffer (48 well: 120µl PLB) is added and with a pipette we scrape twice on the
bottom of the well. PLB is incubated for about 40 minutes at room temperature and
cells are resuspended and transferred into a Kloesch tube. The well is rewashed once
with 60 µl PLB and collected in the same tube. At this point it is possible to freeze
the sample at -20°C for one month. The sample is diluted 1:10 with 1x PLB and 20
µl are transferred onto a 96 well plate. For the measurement of Renilla and Firefly
values we use the luminometer Berthold Centro LB960. LARII and Stop and Glo
solutions are prepared and 1200 µl for priming the machine and 100 µl per well are
transferred into the correct tubes that are connected with the injectors. Luciferase
activity is measured using the software Microwin2000. Firefly substrate: LARII: One
tablet is dissolved in Luciferase assay Buffer II and aliquoted in 2 ml tubes and stored
at -80°C. Stop and Glo solution: Stop and Glo substrate is diluted 1:50 with Stop
and Glo Buffer.
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Table 8.1: Percental distribution of cell types emerging in AB2.2, A5, H3, He2P11K13/5
(He2), and Hi2P11K15/6 (Hi2) aggregates measured by FACS analysis (Figure 4.7; Figure
4.13). Anti-cTnT, anti-SMA, anti-beta3-tubulin, anti-FOXA2, anti-GFAP, anti-vWF
antibodies were used in concentration 1:200, while secondary anti-mouse Alexa Fluor488
and anti-rabbit Alexa647 antibodies 1:500. For each cell line and used antibody the
same gate was set.
AB2.2 A5 H3 He2 Hi2
cTnT 0.25 % 0.49 % 0.065 % 0.135 % 0.465 %
SM-actin 64.29 % 88.77 % 48.99 % 82.35 % 92.77 %
beta3-tubulin 0.15 % 0 0.05 % 0.055 % 7.14 %
FOXA2 1.83 % 2.51 % 0.97 % 15.89 % 10.29 %
GFAP 63.62 % 87.47 % 51.79 % 82.10 % 70.18 %
vWF 98.96 % 95.99 % 98.9 % 84.60 % 98.63 %
Table 8.2: Expression relation of indicated markers between differentiated CVPC
(A5, H3) and SSC (He2P11K13/5, Hi2P11K15/6) to AB2.2 cell population (Figure 4.8;
Figure 4.14). Data were obtained from table 8.1 and were divided through AB2.2 data (
CVPC,SSC/AB2.2).
A5 H3 He2 Hi2
cTnT 1.96 0.26 0.54 1.86
SM-actin 1.38 0.76 1.28 1.44
beta3-tubulin 0 0.33 0.37 47.60
FOXA2 1.37 0.53 8.69 5.62
GFAP 1.37 0.81 1.29 1.10
vWF 0.97 1.00 0.85 1.00
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Table 8.3: Percental distribution of cell types emerging in undifferentiated AB2.2, A5,
H3, He2P11K13/5 (He2), and Hi2P11K15/6 (Hi2). Anti-cTnT, anti-SMA, anti-beta3-
tubulin, anti-FOXA2, anti-GFAP, anti-vWF antibodies were used in concentration 1:200,
while secondary anti-mouse Alexa Fluor488 and anti-rabbit Alexa647 antibodies 1:500.
For each cell line and used antibody the same gate was set.
AB2.2 A5 H3 He2 Hi2
cTnT 0.93 % 0 0.35 % 0.24 % 1.15 %
SM-actin 99.88 % 99.46 % 99.63 % 99.42 % 98.31 %
beta3-tubulin 98.83 % 58.63 % 61.66 % 90.09 % 96.40 %
FOXA2 76.26 % 2.09 % 1.76 % 3.42 % 58.29 %
GFAP 99.07 % 96.32 % 97.17 % 97.54 % 98.47 %
vWF 89.13 % 99.15 % 99.09 % 99.22 % 91.28 %
Table 8.4: Expression relation of indicated markers between differentiated and undiffer-
entiated CVPC (A5, H3) and SSC (He2P11K13/5, Hi2P11K15/6), respectively (Figure
4.9; Figure 4.15). Data were obtained from table 8.1 and table 8.3. Data of differentiated
cells were divided through data of undifferentiated cells (differentiated/undifferentiated).
Values for cTnT (A5) are missing due to the fact that a division through 0 is not possible.
A5 H3 He2 Hi2
cTnT / 0.19 0.56 0.40
SM-actin 0.89 0.49 0.83 0.94
beta3-tubulin 0 0 0 0.07
FOXA2 1.20 0.55 4.65 0.18
GFAP 0.91 0.53 0.84 0.71
vWF 0.97 1.00 0.85 1.08
Table 8.5: Cardiomyogenesis in CVPC (A5 and H3), SSC (He2P11K13/5 and
Hi2P11K15/6) and AB2.2 ESC aggregates (Figure 4.10; Figure 4.16). Percentage
of beating aggregates.
AB2.2 A5 H3 He2 Hi2
7 0 0 0 0 0
8 0 0 0 0 0
9 85.00 % 0 0 0 0
10 87.50 % 2.50 % 0 0 0
11 85.00 % 30.00 % 0 0 0
Continued on next page
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12 82.50 % 77.50 % 0 0 0
13 92.50 % 80.00 % 7.50 % 0 0
14 95.00 % 92.50 % 0 0 0
Table 8.6: Influence of retinoic acid (RA) on beating aggregates, (Figure 4.18; Figure
4.19). Retinoic acid (5x10−7 M) is added from day 5 on to aggregates of He2P11K13/5
(He2), A5 and AB2.2. Percentage of beating aggregates. Data are indicated as percentage.
day AB2.2 AB2.2(RA) A5 A5(RA) He2 He2(RA)
7 0 2.86 0 0 0 0
8 0 18.10 0 0 0 0
9 71.04 47.14 0 0 2.50 3.64
10 82.92 44.29 5.63 0 0 2.42
11 87.92 47.14 31.46 4.76 0.83 1.82
12 87.71 50.90 82.92 5.24 7.08 0.91
13 92.50 51.90 84.38 5.71 23.33 1.21
14 91.25 8.89 96.25 8.89 25.21 2.22
15 91.25 4.44 93.33 10 28.13 2.22
16 90.42 2.22 96.67 4.44 64.44 6.67
17 89.58 1.11 96.67 2.22 60.00 6.67
18 89.59 1.11 96.67 0 22.22 6.67
19 74.17 1.67 90.00 0 8.89 6.67
20 65.83 5.00 85.00 0 0 13.33
Table 8.7: FACS analysis of undifferentiated CVPC clone A5-CSX treated with retinoic
acid for 3h, 24h and 3d (Figure 4.21). Determination of EGFP expression of EGFP-
Nkx2.5 reporter cell line (A5-CSX). Data are means of one experiment with duplicates.
Data here presented are FACS values divided by mean value of control (+EGFP).
SD..Standard deviation for indicated time intervals
time CSX(-EGFP) CSX(+EGFP) CSX+RA
3 hours 0 1 0.99
SD 3h 0 0.01 0.01
24 hours 0 1 0.91
SD 24h 0 0.02 0.01
Continued on next page
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3 days 0 1 0.18
SD 3d 0 0.01 0.01
Table 8.8: FACS analysis of differentiated CVPC clone A5-CSX treated with retinoic
acid for 3h and 24h (Figure 4.22). Determination of EGFP expression of aggregated
EGFP-Nkx2.5 reporter cell line (A5-CSX). Data are means of one experiment with
duplicates. Data here presented are FACS values divided by mean value of control
(+EGFP). SD..Standard deviation for indicated time intervals
time CSX(-EGFP) CSX(+EGFP) CSX+RA
3 hours 0 1 0.88
SD 3h 0 0.02 0.09
24 hours 0 1 0.39
SD 24h 0 0.09 0
Table 8.9: Percental incidence of neuron-like cells in retinoic-acid treated differentiated
He2P11K13/5 (He2), Hi2P11K15/6 (Hi2) A5 and AB2.2 (Figure 4.26; Figure 4.27).
Retinoic acid (5x10−7 M) is added from day 5 on to aggregates. Percentage of aggregates
possessing neuron-like cells. Data are indicated as percentage.
day AB2.2 A5 C3 H3 He2 Hi2
7 0 6.00 0 0 0 0
8 0 46.00 3.00 3.33 0 0
9 30 66.00 91.83 79.17 6.30 83.00
10 66.11 90.00 95.33 81.67 75.19 94.50
11 76.67 90.00 95.33 90.00 94.77 95.50
12 89.44 78.67 96.00 80.00 94.07 96.67
13 85.00 73.33 96.00 86.67 95.19 97.33
14 100 46.67 100 100 66.67 84.17
15 100 40.00 85.00 100 66.67 95.00
16 100 33.33 70.00 92.50 60.00 90.00
17 100 33.33 45.00 85.00 60.00 60.00
18 100 33.33 50.00 85.00 50.00 60.00
19 100 50.00 0 60.00 65.00
20 100 60.00 60.00
21 100 65.00
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22 100 60.00
23 100 50.00
Table 8.10: Percental incidence of neuron-like cells in untreated differentiated
He2P11K13/5 (He2), Hi2P11K15/6 (Hi2) A5 and AB2.2 (Figure 4.28). Percentage
of untreated aggregates possessing neuron-like cells. Data are indicated as percentage.
day AB2.2 A5 C3 H3 He2 Hi2
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 1.67 0 0 0 0 0
10 1.67 0 0 0 0 0
11 3.89 0 0 0 0 1.43
12 13.33 0 0 0 2.38 1.43
13 10.56 0 0 0 0 1.43
14 25.00 0 0 0 8.89 0
15 20.00 0 0 0 8.89 5.00
16 30.00 0 0 0 8.33 15.00
17 33.33 0 0 0 8.89 15.00
18 40.00 0 0 0 10.00 20.00
19 26.67 0 0 0 25.00
20 26.67 3.33 15.00
21 26.67 15.00
22 26.67 20.00
23 23.33 10.00
Table 8.11: Percental frequency of neuron-like cells observed in retinoic acid(RA)-
treated and untreated AB2.2, A5, He2P11K13/5 and Hi2P11K15/6 aggregates between
days 14-17 (Figure 4.28, B). Data obtained from table 8.9 and table 8.10. Data represent
mean value of neuron-like cell frequency between day 14 to 17. SD..Standard deviation.
+RA control
AB2.2 100 % 27.08 %
A5 38.3 % 0 %
He2 63.3 % 8.75 %
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Hi2 82.3 % 11.25 %
AB2.2 SD 0 5.8
A5 SD 6.4 0
He2 SD 3.85 0.28
Hi2 SD 15.5 11.09
Table 8.12: Influence of PD98059 (20µM) on beating CVPC A5 aggregates (Figure
4.33). The inhibitor (PD98059) was added from days 0-5, 5-7, 7-10, 10-13. Percentage of
beating aggregates. Dara are indicated as percentage.
day d 0-5 d 5-7 d 7-10 d 10-13 control
6 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0 0
9 0 0 0 0 0
10 2.94 6.52 0 0 20
11 2.94 15.22 59.26 70.59 95
12 41.18 29.79 82.760 93.75 100
13 57.58 42.22 96.43 100 100
14 64.86 52.08 93.33 100 95
15 56.25 52.17 85.29 100 100
16 57.07 53.45 82.65 94.12 100
17 57.89 54.72 80 88.24 100
18 65.12 45.65 70.59 84.21 100
19 66.93 48.47 61.76 74.46 87.50
20 68.75 51.28 52.94 64.71 75
21 54 41.18 28.13 61.90 20
22 52 31.70 29.58 43.02 15
23 50 22.22 31.03 24.14 10
24 26.47 10 0 3.33 0
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Table 8.13: Influence of PD98059 (5µM) on beating aggregates (Figure 4.32).on beating
CVPC A5 aggregates (Figure 4.32). The inhibitor (PD98059) was added from days 0-5.
Percentage of beating aggregates. Dara are indicated as percentage.
day d 0-5 control
6 0 0
7 0 0
8 0 0
9 0 0
10 0 20
11 3.57 95
12 17.86 100
13 36.67 100
14 41.94 95
15 52.17 100
16 49.84 100
17 47.50 100
18 42.86 100
19 45.70 87.50
20 48.72 75
21 37.14 20
Table 8.14: Effect of PD98059 when added for longer time periods, (Figure 4.34). The
inhibitor (5µM) was added from days 0-13 and 5-13. Percentage of beating aggregates.
Dara are indicated as percentage.
day d 5-13 d 0-13 control
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
11 5 0 5
12 30 0 15
13 35 0 25
14 60 13 65
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15 80 13 95
16 90 20 100
17 100 27 100
18 100 33 100
19 100 33 100
20 100 47 100
21 100 67 100
22 100 67 100
23 100 73 100
24 80 85 100
25 70 80 85
26 55 75 80
27 50 75 80
28 40 70 65
29 25 60 50
30 15 45 45
Table 8.15: Effect of PD98059 on Nkx2.5 gene expression (Figure 4.36). The inhibitor
(5µM) was added from days 0-5. FACS analysis was performed by measuring the EGFP
expression. Data are indicated as percentage.PD...PD98059, CSX...A5-CSX2, M...mean,
Sd...standard deviation.
day A5 CSX CSX +PD +PD M(CSX) M(PD) Sd(CSX) Sd(PD)
0 0.24 94.16 94.49 94.32 0.233
7 0.13 48.62 44.25 13.05 28.20 46.43 20.62 3.09 10.71
13 0 6.64 6.79 5.46 5.51 6.71 5.48 0.10 0.03
20 0.33 6.62 9.83 8.27 6.27 8.225 7.27 2.27 11.41
Table 8.16: The Nkx2.5 expression during aggregate development (Figure 4.37). A5-
CSX2 aggregates were made and FACS analysis was performed by measuring the EGFP
expression. Data are mean of EGFP positive cells in a gated population and indicated
as percentage.
day A5 CSX
0 0.03 88.70
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5 0 63.27
7 0.08 58.02
10 0.1 38.65
13 0.03 14.06
Table 8.17: Effect of indicated factors on Nkx2.5 expression in undifferentiated and
differentiated A5-CSX2 cells (Figure 4.39; Figure 4.40; Figure 4.41). EGFP expression
was determined by FACS analysis. Data are mean of EGFP positive cells in a gated
population. BMP2/4 (0.1µg/ml), anti-BMP2/4 (1.5µg/ml), SPARC (3 µg/ml), anti-
SPARC (1:100). FACS values were divided by mean value of CSX control to obtain a
constant basis line that make it able to compare the effect of these factors on Nkx2.5
gene expression. SD..standard deviation for indicated time points.
A5 CSX +SPARC + anti-SPARC + BMP2 + anti-BMP2
Undifferentiated
3 h 0.01 1.00 1.00 0.99 0.99 1.00
24 h 0.00 1.00 0.98 1.00 0.99 0.99
3 d 0.00 1.00 1.00 0.98 0.99 1.00
SD 3 h 0.01 0.01 0.01 0.01 0.01
SD 24 h 0.02 0.03 0.00 0.04 0.03
SD 3 d 0.01 0.03 0.01 0.00 0.01
Differentiated
3 h 0.00 1.00 1.47 1.07 1.14 2.19
24 h 0.00 1.00 0.42 0.46 0.23 0.47
SD 3 h 0.12 0.10 0.09 0.19 0.21
SD 24 h 0.09 0.01 0.01 0.03 0.00
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Zusammenfassung
Ein Herzinfarkt führt zum Verlust an Kardiomyozyten und beeinträchtigt die Herz-
funktion. Neben den konventionellen Therapiemöglichkeiten hat sich eine neue
eröffnet, die Zelltherapie. Hierbei wird der Verlust an Kardiomyozyten durch externe
Stammzellen abgedeckt um die Herzfunktion zu verbessern. Extensive Forschung wird
in diese Richtung betrieben um ein Verständnis über das regenerierende Potential
dieser Zellen zu erhalten, sowie geeignete Kulturbedingungen und Isolierungsmetho-
den zu etablieren. Diese Diplomarbeit befasst sich mit der Charakterisierung und der
Kardiomyogenese von Vorläuferzellen (CVPC und SSC) isoliert vom Herzen und Hirn
der Maus. Wir vermuteten dass die Zellen ein unterschiedliches Differenzierungspo-
tential aufweisen und nur zu bestimmten Zelltypen differenzieren können. Zusätzlich
wurde der Einfluss von positiven kardialen Regulatoren (BMP2 und SPARC), Retinol-
säure sowie der Effekt von MAPK Signalweg auf die Kardiomyogenese von CVPC
beschrieben. Mittels FACS Analyse und Immunfluoreszenz Färbungen konnten wir
zeigen dass CVPCs ein limitiertes Differenzierungspotential besitzen, anders als SSCs,
die multipotent sind. Um den Effekt von Faktoren auf die Nkx2.5 Genexpression in
CVPCs zu untersuchen verwendeten wir eine Nkx2.5-EGFP Reporterzelllinie. Retinol-
säure bewirkte eine Schwächung der Kardiomyogenese sowie eine verminderte Nkx2.5
Genexpression während es zu einer verstärkten neuronalen Differenzierung kam. Dage-
gen konnte SPARC die Nkx2.5 Genexpression stimulieren und der MAPK Signalweg
scheint eine wichtige Rolle in der frühen Herzentwicklung zu spielen. Diese Resultate
zeigen, dass CVPCs eine geeignete Zelllinie darstellt um molekulare Mechanismen
der Kardiomyogenese zu studieren. Die Optimierung von Kulturbedienungen und
Anreicherung von bestimmten Herzzelltypen sind unerlässliche Schritte in Richtung
Stammzelltherapie.
Abstract
A heart failure leads to a loss of cardiomyocytes and impairs heart function. Beside
conventional therapeutic options a new therapy is established, the cell therapy. Here,
the loss of cardiomyocytes is replaced by exogenous cells to improve heart function.
Extensive research is carried on this field to gain understanding of the regenerative
potential of stem cells as well as to establish adequate culture conditions and isolation
methods. This diploma thesis deals with the characterization and cardiomyogenesis
of progenitor cells (CVPCs and SSCs) isolated from the murine heart and brain.
We assumed that the cells possess a diverse differentiation potential and were able
to differentiate only to distinct cell types. We determined the influence of cardiac
regulators (BMP2 and SPARC), retinoic acid and the effect of MAPK signaling on
cardiomyogenesis of CVPCs. FACS analysis and immunofluorescence staining showed
that CVPCs possess a limited differentiation potential, while SSCs seemed to be
multipotent. To investigate the effect of factors on the Nkx2.5 expression in CVPCs
we made use of the Nkx2.5-EGFP reporter cell line. Retinoic acid caused a weakening
in cardiomyogenesis and a decrease in Nkx2.5 expression, while simultaneously
enhancing neuronal differentiation. In contrast, SPARC stimulated Nkx2.5 expression
and MAPK signaling seemed to play a critical role in early heart development. These
results demonstrate that CVPCs represent an adequate cell line to study molecular
mechanism of cardiomyogenesis. The optimization of culture conditions and the
enrichment of distinct cell types are essential steps toward stem cell therapy.
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